uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q17.909 | Q17 | What gene does the drug Tafasitamab target? | The drug Tafasitamab targets the gene CD19. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tafasitamab%" OR LOWER(tradeNames_string) LIKE "%tafasitamab%" OR LOWER(drugSynonyms_string) LIKE "%tafasitamab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3753', 'drugName': 'Tafasitamab', 'tradeNames_string': 'Monjuvi, Monjuvi (tafasitamab-cxix) for injection', 'drugSynonyms_string': 'MOR-00208, MOR00208, MOR208, Mor-208, Mor00208, Tafasitamab, Tafasitamab cxix, Tafasitamab-cxix, XmAb5574, Xmab-5574, Xmab5574', 'linkedDiseasesDrug_string': 'Prolymphocytic Leukemia (MONDO_0001023), Follicular Lymphoma (MONDO_0018906), Chronic Lymphocytic Leukemia (EFO_0000095), Non-Hodgkins Lymphoma (EFO_0005952), Neoplasm (EFO_0000616), Neoplasm Of Mature B-Cells (EFO_0000096), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Diffuse Large B-Cell Lymphoma (EFO_0000403)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD19 (ENSG00000177455)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.679 | Q17 | What gene does the drug Lumasiran target? | The drug Lumasiran targets the gene HAO1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lumasiran%" OR LOWER(tradeNames_string) LIKE "%lumasiran%" OR LOWER(drugSynonyms_string) LIKE "%lumasiran%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1382', 'drugName': 'Lumasiran', 'tradeNames_string': '', 'drugSynonyms_string': 'AD-65585, ALN-65585, ALN-G01, ALN-GO1, Lumasiran', 'linkedDiseasesDrug_string': 'Primary Hyperoxaluria (MONDO_0002474), Nephrolithiasis (EFO_0004253), Primary Hyperoxaluria Type 1 (MONDO_0009823)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HAO1 (ENSG00000101323)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1071', 'drugName': 'Lumasiran Sodium', 'tradeNames_string': 'Oxlumo', 'drugSynonyms_string': 'Lumasiran sodium', 'linkedDiseasesDrug_string': 'Primary Hyperoxaluria Type 1 (MONDO_0009823)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HAO1 (ENSG00000101323)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.261 | Q17 | What gene does the drug Finasteride target? | The drug Finasteride targets the gene SRD5A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%finasteride%" OR LOWER(tradeNames_string) LIKE "%finasteride%" OR LOWER(drugSynonyms_string) LIKE "%finasteride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5461', 'drugName': 'Finasteride', 'tradeNames_string': 'Aindeem, Finasteride, Propecia, Proscar, Prostide', 'drugSynonyms_string': 'Finasteride, MK-906, NSC-741485, NSC-759318', 'linkedDiseasesDrug_string': 'Androgenetic Alopecia (EFO_0004191), Hyperplasia (EFO_0000536), Hypogonadism (MONDO_0002146), Alopecia (MONDO_0004907), Prostate Cancer (MONDO_0008315), Hypotrichosis (MONDO_0003037), Non-Small Cell Lung Carcinoma (EFO_0003060), Benign Prostatic Hyperplasia (EFO_0000284), Acne (EFO_0003894), Retinopathy (EFO_0003839), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SRD5A2 (ENSG00000277893)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.851 | Q17 | What gene does the drug Rocuronium target? | The drug Rocuronium targets 5 genes: CHRNB1, CHRNA1, CHRND, CHRNE and CHRNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rocuronium%" OR LOWER(tradeNames_string) LIKE "%rocuronium%" OR LOWER(drugSynonyms_string) LIKE "%rocuronium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1958', 'drugName': 'Rocuronium', 'tradeNames_string': '', 'drugSynonyms_string': 'Rocuronium, Rocuronium cation, Rocuronium ion', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cardiac Arrest (EFO_0009492), Prostate Cancer (MONDO_0008315), Pain (EFO_0003843), Back Pain (HP_0003418), Kidney Disease (EFO_0003086), Lung Neoplasm (MONDO_0021117), Organophosphate Poisoning (EFO_0010581), Bone Fracture (EFO_0003931), Myalgia (HP_0003326)', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_3086', 'drugName': 'Rocuronium Bromide', 'tradeNames_string': 'Esmeron, Rocuronium bromide, Zemuron', 'drugSynonyms_string': 'ORG 9426, ORG-9426, Rocuronium bromide', 'linkedDiseasesDrug_string': 'Cardiac Arrest (EFO_0009492), Back Pain (HP_0003418)', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.874 | Q17 | What gene does the drug Carbinoxamine target? | The drug Carbinoxamine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%carbinoxamine%" OR LOWER(tradeNames_string) LIKE "%carbinoxamine%" OR LOWER(drugSynonyms_string) LIKE "%carbinoxamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4593', 'drugName': 'Carbinoxamine Maleate', 'tradeNames_string': 'Carbinoxamine maleate, Clistin, Davenol, Karbinal er', 'drugSynonyms_string': 'Carbinoxamine maleate, NSC-62362', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Angioedema (EFO_0005532), Vasomotor Rhinitis (EFO_0007533), Urticaria (EFO_0005531)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1625', 'drugName': 'Carbinoxamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Carbinoxamine, Clistin, Palgic', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Angioedema (EFO_0005532), Vasomotor Rhinitis (EFO_0007533), Allergic Disease (MONDO_0005271), Urticaria (EFO_0005531)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1564 | Q17 | What gene does the drug Ing-1 target? | The drug Ing-1 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene EPCAM. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ing-1%" OR LOWER(tradeNames_string) LIKE "%ing-1%" OR LOWER(drugSynonyms_string) LIKE "%ing-1%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5093', 'drugName': 'Ing-1', 'tradeNames_string': '', 'drugSynonyms_string': 'HEMAB, ING-1, Ing-1', 'linkedDiseasesDrug_string': 'Adenocarcinoma (EFO_0000228)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'EPCAM (ENSG00000119888)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.141 | Q17 | What gene does the drug Troglitazone target? | The drug Troglitazone targets the gene PPARG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%troglitazone%" OR LOWER(tradeNames_string) LIKE "%troglitazone%" OR LOWER(drugSynonyms_string) LIKE "%troglitazone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1190', 'drugName': 'Troglitazone', 'tradeNames_string': 'Prelay, Rezulin, Romozin', 'drugSynonyms_string': 'CI-991, CS-045, GR-92132X, GR92132X, Rezulin, Troglitazone', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Sarcoma (EFO_0000691)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.900 | Q17 | What gene does the drug Ruxolitinib Phosphate target? | The drug Ruxolitinib Phosphate targets 2 genes: JAK1 and JAK2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ruxolitinib phosphate%" OR LOWER(tradeNames_string) LIKE "%ruxolitinib phosphate%" OR LOWER(drugSynonyms_string) LIKE "%ruxolitinib phosphate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1727', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_string': 'Jakafi, Opzelura', 'drugSynonyms_string': 'INCB-018424 PHOSPHATE, INCB-018424 SALT, INCB-18424 PHOSPHATE, INCB018424 PHOSPHATE, INCB018424 SALT, Opzelura, Ruxolitinib (as phosphate), Ruxolitinib monophosphate, Ruxolitinib phosphate', 'linkedDiseasesDrug_string': 'Myelofibrosis (HP_0011974), Psoriasis (EFO_0000676), Primary Myelofibrosis (EFO_0002430), Fallopian Tube Cancer (MONDO_0002158), Chronic Lymphocytic Leukemia (EFO_0000095), Alopecia Areata (EFO_0004192), Atopic Eczema (EFO_0000274), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Polycythemia Vera (EFO_0002429), Endometrioid Carcinoma (EFO_0000466), Malaria (EFO_0001068), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'JAK1 (ENSG00000162434), JAK2 (ENSG00000096968)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1728', 'drugName': 'Ruxolitinib Phosphate', 'tradeNames_string': 'Jakafi, Opzelura', 'drugSynonyms_string': 'INCB-018424 PHOSPHATE, INCB-018424 SALT, INCB-18424 PHOSPHATE, INCB018424 PHOSPHATE, INCB018424 SALT, Opzelura, Ruxolitinib (as phosphate), Ruxolitinib monophosphate, Ruxolitinib phosphate', 'linkedDiseasesDrug_string': 'Myelofibrosis (HP_0011974), Psoriasis (EFO_0000676), Primary Myelofibrosis (EFO_0002430), Fallopian Tube Cancer (MONDO_0002158), Chronic Lymphocytic Leukemia (EFO_0000095), Alopecia Areata (EFO_0004192), Atopic Eczema (EFO_0000274), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Polycythemia Vera (EFO_0002429), Endometrioid Carcinoma (EFO_0000466), Malaria (EFO_0001068), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'JAK1 (ENSG00000162434), JAK2 (ENSG00000096968)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1839 | Q17 | What gene does the drug Oregovomab target? | The drug Oregovomab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MUC16. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oregovomab%" OR LOWER(tradeNames_string) LIKE "%oregovomab%" OR LOWER(drugSynonyms_string) LIKE "%oregovomab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3687', 'drugName': 'Oregovomab', 'tradeNames_string': 'Ovarex', 'drugSynonyms_string': 'Oregovamab, Oregovomab, mAb-B43.13', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Fallopian Tube Cancer (MONDO_0002158), Ovarian Neoplasm (EFO_0003893), Peritoneum Cancer (MONDO_0002087), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC16 (ENSG00000181143)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.555 | Q17 | What gene does the drug Chlorpheniramine target? | The drug Chlorpheniramine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%chlorpheniramine%" OR LOWER(tradeNames_string) LIKE "%chlorpheniramine%" OR LOWER(drugSynonyms_string) LIKE "%chlorpheniramine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6213', 'drugName': 'Dexchlorpheniramine Maleate', 'tradeNames_string': 'Dexchlorpheniramine maleate, Mylaramine, Polaramine', 'drugSynonyms_string': 'Chlorpheniramine d-form maleate, Chlorpheniramine maleate, (s)-, D-chlorpheniramine maleate, Dexchlorpheniramine maleate, NSC-759156', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Multiple Sclerosis (MONDO_0005301), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Angioedema (EFO_0005532), Vasomotor Rhinitis (EFO_0007533), Allergic Rhinitis (EFO_0005854), Allergic Disease (MONDO_0005271), Urticaria (EFO_0005531), Sunburn (EFO_0003958)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4827', 'drugName': 'Chlorpheniramine', 'tradeNames_string': '', 'drugSynonyms_string': 'Antagonate, Chlor-Trimeton, Chlorphenamine, Chlorpheniramine, Isoclor, Kloromin, Phenetron, Teldrin', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Chronic Hepatitis B Virus Infection (EFO_0004239), Seasonal Allergic Rhinitis (EFO_0003956), Cough (HP_0012735), Allergic Rhinitis (EFO_0005854), Influenza (EFO_0007328), Allergic Disease (MONDO_0005271), Sunburn (EFO_0003958)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_221', 'drugName': 'Chlorpheniramine Maleate', 'tradeNames_string': 'Allercalm allergy relief, Allerief, Alunex, Antagonate, Calimal, Chlor-trimeton, Chlorphenamine, Chlorpheniramine maleate, Efidac 24 chlorpheniramine maleate, Hayleve, Kloromin, Phenetron, Piriject, Piriton, Piriton allergy, Pyridamal 100, Rhino-syrup allergy, Rimarin, Teldrin', 'drugSynonyms_string': '(+)-Chlorpheniramine Maleate, Chlorphenamine hydrogen maleate, Chlorphenamine maleate, Chlorphenamini hydrogenomaleas, Chlorpheniramine Maleate, Chlorpheniramine maleate, Chlorprophenpyridamine maleate, Efidac, Histaspan, NSC-756684, Neorestamin, Pyridamal, Synistamin', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Seasonal Allergic Rhinitis (EFO_0003956), Cough (HP_0012735), Allergic Rhinitis (EFO_0005854), Sunburn (EFO_0003958)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_706', 'drugName': 'Chlorpheniramine Polistirex', 'tradeNames_string': '', 'drugSynonyms_string': 'Chlorpheniramine polistirex', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3635', 'drugName': 'Dexchlorpheniramine', 'tradeNames_string': '', 'drugSynonyms_string': 'Chlorphenamine, (s)-, Chlorpheniramine d-form, Chlorpheniramine, (s)-, Chlorpheniramine, d-, Dapriton, Dexchlorpheniramine', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Multiple Sclerosis (MONDO_0005301), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Angioedema (EFO_0005532), Vasomotor Rhinitis (EFO_0007533), Allergic Rhinitis (EFO_0005854), Allergic Disease (MONDO_0005271), Urticaria (EFO_0005531), Sunburn (EFO_0003958)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.323 | Q17 | What gene does the drug Ethchlorvynol target? | The drug Ethchlorvynol targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ethchlorvynol%" OR LOWER(tradeNames_string) LIKE "%ethchlorvynol%" OR LOWER(drugSynonyms_string) LIKE "%ethchlorvynol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3295', 'drugName': 'Ethchlorvynol', 'tradeNames_string': 'Ethchlorvynol, Placidyl', 'drugSynonyms_string': 'Alvinol, Arvynol, Ethchlorvynol, Ethchlorvynol civ, NSC-30372, Normoson, Nostel, Roeridorm, Serenesil, Serensil', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1961, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1854 | Q17 | What gene does the drug Batoprotafib target? | The drug Batoprotafib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PTPN11. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%batoprotafib%" OR LOWER(tradeNames_string) LIKE "%batoprotafib%" OR LOWER(drugSynonyms_string) LIKE "%batoprotafib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6363', 'drugName': 'Batoprotafib', 'tradeNames_string': '', 'drugSynonyms_string': 'Batoprotafib, Ptpn11 inhibitor tno155, Shp2 inhibitor tno155, TNO-155, TNO155, Tno 155, Tno-155, Tno155', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'PTPN11 (ENSG00000179295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1235 | Q17 | What gene does the drug Menthol target? | The drug Menthol targets 2 genes: TRPM8 and TRPA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%menthol%" OR LOWER(tradeNames_string) LIKE "%menthol%" OR LOWER(drugSynonyms_string) LIKE "%menthol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5721', 'drugName': 'Menthol', 'tradeNames_string': "Aqua-cool, Aquasoothe, Arjun, Catarrh, Dermacool, Fisherman's friend lozenges, Halls, Karvol, Lockets, Meggezones, Muirs, Therapeutic mineral ice, Tixylix decongestant inh, Vocalzone", 'drugSynonyms_string': 'Dl-menthol, FEMA NO. 2665, Meggezone, Menthol, Menthol racemate, Menthol, cis-1,3,trans-1,4-, Menthol, dl-, NSC-2603, Rac-menthol, Racementhol', 'linkedDiseasesDrug_string': 'Tendinopathy (EFO_1001434), Pain (EFO_0003843), Cough (HP_0012735), Muscle Spasm (HP_0003394), Injury (EFO_0000546), Muscle Cramp (EFO_0009846), Bronchitis (EFO_0009661), Gastric Cancer (MONDO_0001056), Headache (HP_0002315), Herpes Labialis (EFO_1001347), Nicotine Dependence (EFO_0003768), Bursitis (MONDO_0002471), Hypertension (EFO_0000537), Arthritis (EFO_0005856), Oral Ulcer (HP_0000155), Frozen Shoulder (EFO_1000941), Tendinitis (MONDO_0004857), Sunburn (EFO_0003958), Pruritus (HP_0000989), Asthma (MONDO_0004979), Pharyngitis (MONDO_0002258), Common Cold (EFO_0007214), Hemorrhoid (EFO_0009552), Back Pain (HP_0003418), Sprain (EFO_0009582), Nasal Congestion (HP_0001742), Myalgia (HP_0003326), Skin Infection (MONDO_0021201), Osteoarthritis (MONDO_0005178), Arthralgia (HP_0002829), Diabetic Neuropathy (EFO_1000783), Burn (EFO_0009516), Dysphagia (HP_0002015)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TRPA1 (ENSG00000104321), TRPM8 (ENSG00000144481)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5722', 'drugName': 'Menthol', 'tradeNames_string': "Aqua-cool, Aquasoothe, Arjun, Catarrh, Dermacool, Fisherman's friend lozenges, Halls, Karvol, Lockets, Meggezones, Muirs, Therapeutic mineral ice, Tixylix decongestant inh, Vocalzone", 'drugSynonyms_string': 'Dl-menthol, FEMA NO. 2665, Meggezone, Menthol, Menthol racemate, Menthol, cis-1,3,trans-1,4-, Menthol, dl-, NSC-2603, Rac-menthol, Racementhol', 'linkedDiseasesDrug_string': 'Tendinopathy (EFO_1001434), Pain (EFO_0003843), Cough (HP_0012735), Muscle Spasm (HP_0003394), Injury (EFO_0000546), Muscle Cramp (EFO_0009846), Bronchitis (EFO_0009661), Gastric Cancer (MONDO_0001056), Headache (HP_0002315), Herpes Labialis (EFO_1001347), Nicotine Dependence (EFO_0003768), Bursitis (MONDO_0002471), Hypertension (EFO_0000537), Arthritis (EFO_0005856), Oral Ulcer (HP_0000155), Frozen Shoulder (EFO_1000941), Tendinitis (MONDO_0004857), Sunburn (EFO_0003958), Pruritus (HP_0000989), Asthma (MONDO_0004979), Pharyngitis (MONDO_0002258), Common Cold (EFO_0007214), Hemorrhoid (EFO_0009552), Back Pain (HP_0003418), Sprain (EFO_0009582), Nasal Congestion (HP_0001742), Myalgia (HP_0003326), Skin Infection (MONDO_0021201), Osteoarthritis (MONDO_0005178), Arthralgia (HP_0002829), Diabetic Neuropathy (EFO_1000783), Burn (EFO_0009516), Dysphagia (HP_0002015)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TRPA1 (ENSG00000104321), TRPM8 (ENSG00000144481)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1726 | Q17 | What gene does the drug Abt-925 target? | The drug Abt-925 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene DRD3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%abt-925%" OR LOWER(tradeNames_string) LIKE "%abt-925%" OR LOWER(drugSynonyms_string) LIKE "%abt-925%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3906', 'drugName': 'Abt-925', 'tradeNames_string': '', 'drugSynonyms_string': 'A-437203, Abt-925', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'DRD3 (ENSG00000151577)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.564 | Q17 | What gene does the drug Clothiapine target? | The drug Clothiapine targets 9 genes: DRD4, HTR3D, HTR3C, HTR2A, HTR2B, HTR3E, HTR3B, HTR2C and HTR3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clothiapine%" OR LOWER(tradeNames_string) LIKE "%clothiapine%" OR LOWER(drugSynonyms_string) LIKE "%clothiapine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2386', 'drugName': 'Clothiapine', 'tradeNames_string': '', 'drugSynonyms_string': 'Clothiapine, Clotiapine, Entumin, HF-2159', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2B (ENSG00000135914), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD4 (ENSG00000069696), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_2387', 'drugName': 'Clothiapine', 'tradeNames_string': '', 'drugSynonyms_string': 'Clothiapine, Clotiapine, Entumin, HF-2159', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2B (ENSG00000135914), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD4 (ENSG00000069696), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_2388', 'drugName': 'Clothiapine', 'tradeNames_string': '', 'drugSynonyms_string': 'Clothiapine, Clotiapine, Entumin, HF-2159', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2B (ENSG00000135914), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD4 (ENSG00000069696), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'numberLinkedTargets': 9}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.142 | Q17 | What gene does the drug Ozanimod target? | The drug Ozanimod targets the gene S1PR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ozanimod%" OR LOWER(tradeNames_string) LIKE "%ozanimod%" OR LOWER(drugSynonyms_string) LIKE "%ozanimod%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1976', 'drugName': 'Ozanimod', 'tradeNames_string': '', 'drugSynonyms_string': 'Ozanimod, RPC-1063, RPC1063', 'linkedDiseasesDrug_string': "Crohn'S Disease (EFO_0000384), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Covid-19 (MONDO_0100096), Ulcerative Colitis (EFO_0000729), Immune System Disease (EFO_0000540)", 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR1 (ENSG00000170989)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5399', 'drugName': 'Ozanimod Hydrochloride', 'tradeNames_string': 'Zeposia', 'drugSynonyms_string': 'Ozanimod hydrochloride, RPC-1063 HCL, RPC1063 HCL', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR1 (ENSG00000170989)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1736 | Q17 | What gene does the drug Eslicarbazepine Acetate target? | The drug Eslicarbazepine Acetate targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eslicarbazepine acetate%" OR LOWER(tradeNames_string) LIKE "%eslicarbazepine acetate%" OR LOWER(drugSynonyms_string) LIKE "%eslicarbazepine acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4666', 'drugName': 'Eslicarbazepine Acetate', 'tradeNames_string': 'Aptiom, Erelib, Pazzul, Stedesa, Zebinix', 'drugSynonyms_string': 'BIA 2-093, BIA-2-093, BIA-2093, Eslicarbazepine acetate, SEP - 0002093, SEP-0002093', 'linkedDiseasesDrug_string': 'Diabetic Neuropathy (EFO_1000783), Postherpetic Neuralgia (MONDO_0041052), Bipolar I Disorder (EFO_0009963), Migraine Disorder (MONDO_0005277), Neuropathic Pain (EFO_0005762), Fibromyalgia (EFO_0005687), Partial Epilepsy (EFO_0004263), Epilepsy (EFO_0000474), Seizure (HP_0001250), Complex Partial Epilepsy (EFO_1000877)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.537 | Q17 | What gene does the drug Gsk-1292263 target? | The drug Gsk-1292263 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene GPR119. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gsk-1292263%" OR LOWER(tradeNames_string) LIKE "%gsk-1292263%" OR LOWER(drugSynonyms_string) LIKE "%gsk-1292263%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5541', 'drugName': 'Gsk-1292263', 'tradeNames_string': '', 'drugSynonyms_string': 'GSK-1292263, GSK-1292263A, GSK-263A, GSK1292263, Gsk 1292263, Gsk-1292263, Gsk1292263', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Disorder Of Lipid Metabolism (Orphanet_309005)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GPR119 (ENSG00000147262)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.227 | Q17 | What gene does the drug Suvorexant target? | The drug Suvorexant targets 2 genes: HCRTR2 and HCRTR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%suvorexant%" OR LOWER(tradeNames_string) LIKE "%suvorexant%" OR LOWER(drugSynonyms_string) LIKE "%suvorexant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5935', 'drugName': 'Suvorexant', 'tradeNames_string': 'Belsomra', 'drugSynonyms_string': 'MK-4305, MK4305, Suvorexant', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Sleep Apnea (EFO_0003877), Opioid Use Disorder (EFO_0010702), Smoking Cessation (EFO_0004319), Sleep Disorder (EFO_0008568), Nicotine Dependence (EFO_0003768), Delirium (EFO_0009267), Insomnia (EFO_0004698), Alcohol Dependence (MONDO_0007079), Restless Legs Syndrome (EFO_0004270)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HCRTR2 (ENSG00000137252), HCRTR1 (ENSG00000121764)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.730 | Q17 | What gene does the drug Indomethacin Sodium target? | The drug Indomethacin Sodium targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%indomethacin sodium%" OR LOWER(tradeNames_string) LIKE "%indomethacin sodium%" OR LOWER(drugSynonyms_string) LIKE "%indomethacin sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4252', 'drugName': 'Indomethacin Sodium', 'tradeNames_string': 'Indocin, Indomethacin sodium', 'drugSynonyms_string': 'Indometacin sodium, Indometacin sodium hydrate, Indometacin sodium trihydrate, Indomethacin sodium, Indomethacin sodium anhydrous, Indomethacin sodium salt trihydrate, Indomethacin sodium trihydrate, Sodium indomethacin, Sodium indomethacin trihydrate', 'linkedDiseasesDrug_string': 'Inflammation (MP_0001845)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.793 | Q17 | What gene does the drug Flurbiprofen Sodium target? | The drug Flurbiprofen Sodium targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%flurbiprofen sodium%" OR LOWER(tradeNames_string) LIKE "%flurbiprofen sodium%" OR LOWER(drugSynonyms_string) LIKE "%flurbiprofen sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2737', 'drugName': 'Flurbiprofen Sodium', 'tradeNames_string': 'Ansaid, Flurbiprofen sodium, Occufen, Ocufen, Zepolas', 'drugSynonyms_string': 'Flurbiprofen sodium, Flurbiprofen sodium anhydrous, Flurbiprofen sodium dihydrate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1718 | Q17 | What gene does the drug Doxylamine target? | The drug Doxylamine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%doxylamine%" OR LOWER(tradeNames_string) LIKE "%doxylamine%" OR LOWER(drugSynonyms_string) LIKE "%doxylamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3456', 'drugName': 'Doxylamine Succinate', 'tradeNames_string': 'Decapryn, Doxy-sleep-aid, Doxylamine succinate, Unisom', 'drugSynonyms_string': 'Alsodorm, Donormil, Donormyl, Dormidina, Doxylamine hydrogen succinate, Doxylamine succinate, Gittalun, Hoggar n, Meraprina, NSC-74772', 'linkedDiseasesDrug_string': 'Nausea And Vomiting (HP_0002017), Infection (EFO_0000544), Allergic Rhinitis (EFO_0005854)', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1436', 'drugName': 'Doxylamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Decapryn, Doxy-Sleep-Aid, Doxylamine, Unisom', 'linkedDiseasesDrug_string': 'Nausea And Vomiting (HP_0002017), Allergic Disease (MONDO_0005271), Allergic Rhinitis (EFO_0005854), Infection (EFO_0000544)', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.994 | Q17 | What gene does the drug Tirofiban target? | The drug Tirofiban targets 2 genes: ITGB3 and ITGA2B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tirofiban%" OR LOWER(tradeNames_string) LIKE "%tirofiban%" OR LOWER(drugSynonyms_string) LIKE "%tirofiban%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2127', 'drugName': 'Tirofiban', 'tradeNames_string': '', 'drugSynonyms_string': 'Aggrastat, Agrastat, L-700462, MK-383, Tirofiban', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Coronary Artery Disease (EFO_0001645), Ischemic Stroke (HP_0002140), Viral Pneumonia (EFO_0007541), Stroke (EFO_0000712), Covid-19 (MONDO_0100096), Myocardial Infarction (EFO_0000612), Respiratory Failure (EFO_0009686), Venous Thromboembolism (EFO_0004286), Acute Coronary Syndrome (EFO_0005672), Acute Myocardial Infarction (EFO_0008583), Renal Insufficiency (HP_0000083)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ITGB3 (ENSG00000259207), ITGA2B (ENSG00000005961)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2897', 'drugName': 'Tirofiban Hydrochloride', 'tradeNames_string': 'Aggrastat', 'drugSynonyms_string': 'L-700,462, L-700462, MK-383, Tirofiban hcl, Tirofiban hydrochloride, Tirofiban hydrochloride anhydrous', 'linkedDiseasesDrug_string': 'Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ITGB3 (ENSG00000259207), ITGA2B (ENSG00000005961)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.415 | Q17 | What gene does the drug Betaine target? | The drug Betaine targets 2 genes: BHMT2 and BHMT. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%betaine%" OR LOWER(tradeNames_string) LIKE "%betaine%" OR LOWER(drugSynonyms_string) LIKE "%betaine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3565', 'drugName': 'Betaine', 'tradeNames_string': 'Cystadane', 'drugSynonyms_string': 'Abromine, Betaine, Betaine anhydrous, Betaine, anhydrous, Cystadane, FEMA NO. 4223, NSC-166511', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Male Infertility (EFO_0004248), Xerostomia (EFO_0009869), Non-Alcoholic Steatohepatitis (EFO_1001249), Obesity (EFO_0001073), Chronic Hepatitis C Virus Infection (EFO_0004220), Homocystinuria (MONDO_0004737), Primary Hyperoxaluria (MONDO_0002474), Hepatitis C Virus Infection (EFO_0003047)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'BHMT (ENSG00000145692), BHMT2 (ENSG00000132840)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1270', 'drugName': 'Betaine Hydrochloride', 'tradeNames_string': 'Acidol pepsin, Cystadane', 'drugSynonyms_string': 'Betaine HCl, Betaine hcl, Betaine hydrochloride, Betainum muriaticum, Lycine hydrochloride, NSC-32191, NSC-3976', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'BHMT (ENSG00000145692), BHMT2 (ENSG00000132840)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.329 | Q17 | What gene does the drug Glembatumumab Vedotin target? | The drug Glembatumumab Vedotin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 16 genes: TUBB, TUBA4A, TUBA3E, TUBB3, GPNMB, TUBB4B, TUBB2A, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C and TUBA1B | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%glembatumumab vedotin%" OR LOWER(tradeNames_string) LIKE "%glembatumumab vedotin%" OR LOWER(drugSynonyms_string) LIKE "%glembatumumab vedotin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6314', 'drugName': 'Glembatumumab Vedotin', 'tradeNames_string': '', 'drugSynonyms_string': 'CDX-011, CR-011-VCMMAE, Glembatumumab vedotin', 'linkedDiseasesDrug_string': 'Melanoma (EFO_0000756), Squamous Cell Lung Carcinoma (EFO_0000708), Osteosarcoma (EFO_0000637), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GPNMB (ENSG00000136235), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_6315', 'drugName': 'Glembatumumab Vedotin', 'tradeNames_string': '', 'drugSynonyms_string': 'CDX-011, CR-011-VCMMAE, Glembatumumab vedotin', 'linkedDiseasesDrug_string': 'Melanoma (EFO_0000756), Squamous Cell Lung Carcinoma (EFO_0000708), Osteosarcoma (EFO_0000637), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GPNMB (ENSG00000136235), TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1098 | Q17 | What gene does the drug Docetaxel target? | The drug Docetaxel targets 15 genes: TUBB, TUBA4A, TUBA3E, TUBB3, TUBB4B, TUBB2A, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C and TUBA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%docetaxel%" OR LOWER(tradeNames_string) LIKE "%docetaxel%" OR LOWER(drugSynonyms_string) LIKE "%docetaxel%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1267', 'drugName': 'Docetaxel', 'tradeNames_string': '', 'drugSynonyms_string': 'RP-56976, Taxotere', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Multiple Myeloma (EFO_0001378), Malignant Colon Neoplasm (MONDO_0021063), Cervical Adenocarcinoma (EFO_0001416), Inflammatory Breast Carcinoma (EFO_1000984), Testicular Neoplasm (EFO_0004281), Lung Adenocarcinoma (EFO_0000571), Urinary Bladder Carcinoma (MONDO_0004986), Pharynx Cancer (EFO_0005577), Malignant Tumor Of Neck (MONDO_0021310), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Breast Ductal Carcinoma In Situ (EFO_0000432), Endometrial Neoplasm (EFO_0004230), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Osteosarcoma (EFO_0000637), Ewing Sarcoma (EFO_0000174), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Leiomyosarcoma (EFO_0000564), Transitional Cell Carcinoma (EFO_1000601), Thyroid Gland Undifferentiated (Anaplastic) Carcinoma (EFO_1000595), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Cancer (MONDO_0004992), Gastrointestinal Stromal Tumor (MONDO_0011719), Squamous Cell Lung Carcinoma (EFO_0000708), Male Reproductive Organ Cancer (EFO_0007355), Vaginal Cancer (MONDO_0001402), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Prostate Carcinoma (EFO_0001663), Neuroendocrine Carcinoma (MONDO_0002120), Hepatocellular Carcinoma (EFO_0000182), Uterine Neoplasm (EFO_0003859), Gastric Adenocarcinoma (EFO_0000503), Gastric Carcinoma (EFO_0000178), Metastasis (EFO_0009708), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Oropharynx Cancer (EFO_1001931), Triple-Negative Breast Cancer (EFO_0005537), Salivary Gland Cancer (MONDO_0004669), Laryngeal Neoplasm (EFO_0003817), Urogenital Neoplasm (EFO_0003863), Esophageal Squamous Cell Carcinoma (EFO_0005922), Non-Small Cell Lung Carcinoma (EFO_0003060), Head And Neck Carcinoma (MONDO_0002038), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Esophageal Carcinoma (EFO_0002916), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Gastrointestinal Disease (EFO_0010282), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Tonsil Cancer (EFO_1001214), Lymphoma (EFO_0000574), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Biliary Tract Cancer (MONDO_0003060), Paranasal Sinus Neoplasm (EFO_0003866), Penile Cancer (MONDO_0001325), Pancreatic Carcinoma (EFO_0002618), Cachexia (HP_0004326), Colorectal Cancer (MONDO_0005575), Peritoneum Cancer (MONDO_0002087), Allergic Disease (MONDO_0005271), Biliary Tract Neoplasm (EFO_0003891), Chronic Myeloproliferative Disorder (EFO_0002428), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Testicular Carcinoma (EFO_0005088), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Synovial Sarcoma (EFO_0001376), Laryngeal Carcinoma (MONDO_0002358), Stomach Neoplasm (EFO_0003897), Anorexia (HP_0002039), Oral Cavity Cancer (EFO_0005570), Neoplasm Of Esophagus (MONDO_0021355), Peritoneal Neoplasm (EFO_1001100), Metastatic Melanoma (EFO_0002617), Endometrial Cancer (MONDO_0011962), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Vulva Cancer (MONDO_0001528), Prostate Cancer (MONDO_0008315), Neutropenia (MONDO_0001475), Male Breast Carcinoma (EFO_0006861), Oral Squamous Cell Carcinoma (EFO_0000199), Urethra Cancer (MONDO_0004192), Salivary Gland Carcinoma (MONDO_0000521), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Kidney Neoplasm (EFO_0003865), Endometrioid Carcinoma (EFO_0000466), Ovarian Neoplasm (EFO_0003893), Anal Carcinoma (MONDO_0003199), Head And Neck Malignant Neoplasia (EFO_0006859), Mediastinal Cancer (EFO_0007362), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Fatigue (HP_0012378), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}, {'UUID': 'DrugGeneTargets_v2_2177', 'drugName': 'Docetaxel', 'tradeNames_string': 'Docefrez, Docetaxel, Taxceus, Taxotere', 'drugSynonyms_string': 'Bind 014, CKD-810, Docetaxel, Docetaxel (as trihydrate), Docetaxel anhydrous, Docetaxel hydrate, Docetaxel trihydrate, NSC-628503, RP 56976, RP-56976, XRP6976', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Multiple Myeloma (EFO_0001378), Malignant Colon Neoplasm (MONDO_0021063), Cervical Adenocarcinoma (EFO_0001416), Inflammatory Breast Carcinoma (EFO_1000984), Testicular Neoplasm (EFO_0004281), Lung Adenocarcinoma (EFO_0000571), Urinary Bladder Carcinoma (MONDO_0004986), Pharynx Cancer (EFO_0005577), Malignant Tumor Of Neck (MONDO_0021310), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Breast Ductal Carcinoma In Situ (EFO_0000432), Endometrial Neoplasm (EFO_0004230), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Osteosarcoma (EFO_0000637), Ewing Sarcoma (EFO_0000174), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Leiomyosarcoma (EFO_0000564), Transitional Cell Carcinoma (EFO_1000601), Thyroid Gland Undifferentiated (Anaplastic) Carcinoma (EFO_1000595), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Cancer (MONDO_0004992), Gastrointestinal Stromal Tumor (MONDO_0011719), Squamous Cell Lung Carcinoma (EFO_0000708), Male Reproductive Organ Cancer (EFO_0007355), Vaginal Cancer (MONDO_0001402), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Prostate Carcinoma (EFO_0001663), Neuroendocrine Carcinoma (MONDO_0002120), Hepatocellular Carcinoma (EFO_0000182), Uterine Neoplasm (EFO_0003859), Gastric Adenocarcinoma (EFO_0000503), Gastric Carcinoma (EFO_0000178), Metastasis (EFO_0009708), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Oropharynx Cancer (EFO_1001931), Triple-Negative Breast Cancer (EFO_0005537), Salivary Gland Cancer (MONDO_0004669), Laryngeal Neoplasm (EFO_0003817), Urogenital Neoplasm (EFO_0003863), Esophageal Squamous Cell Carcinoma (EFO_0005922), Non-Small Cell Lung Carcinoma (EFO_0003060), Head And Neck Carcinoma (MONDO_0002038), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Esophageal Carcinoma (EFO_0002916), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Gastrointestinal Disease (EFO_0010282), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Tonsil Cancer (EFO_1001214), Lymphoma (EFO_0000574), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Biliary Tract Cancer (MONDO_0003060), Paranasal Sinus Neoplasm (EFO_0003866), Penile Cancer (MONDO_0001325), Pancreatic Carcinoma (EFO_0002618), Cachexia (HP_0004326), Colorectal Cancer (MONDO_0005575), Peritoneum Cancer (MONDO_0002087), Allergic Disease (MONDO_0005271), Biliary Tract Neoplasm (EFO_0003891), Chronic Myeloproliferative Disorder (EFO_0002428), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Testicular Carcinoma (EFO_0005088), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Synovial Sarcoma (EFO_0001376), Laryngeal Carcinoma (MONDO_0002358), Stomach Neoplasm (EFO_0003897), Anorexia (HP_0002039), Oral Cavity Cancer (EFO_0005570), Neoplasm Of Esophagus (MONDO_0021355), Peritoneal Neoplasm (EFO_1001100), Metastatic Melanoma (EFO_0002617), Endometrial Cancer (MONDO_0011962), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Vulva Cancer (MONDO_0001528), Prostate Cancer (MONDO_0008315), Neutropenia (MONDO_0001475), Male Breast Carcinoma (EFO_0006861), Oral Squamous Cell Carcinoma (EFO_0000199), Urethra Cancer (MONDO_0004192), Salivary Gland Carcinoma (MONDO_0000521), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Kidney Neoplasm (EFO_0003865), Endometrioid Carcinoma (EFO_0000466), Ovarian Neoplasm (EFO_0003893), Anal Carcinoma (MONDO_0003199), Head And Neck Malignant Neoplasia (EFO_0006859), Mediastinal Cancer (EFO_0007362), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Fatigue (HP_0012378), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.303 | Q17 | What gene does the drug Andolast target? | The drug Andolast is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene KCNMA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%andolast%" OR LOWER(tradeNames_string) LIKE "%andolast%" OR LOWER(drugSynonyms_string) LIKE "%andolast%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5782', 'drugName': 'Andolast', 'tradeNames_string': '', 'drugSynonyms_string': 'Andolast, Cr2039', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNMA1 (ENSG00000156113)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1259 | Q17 | What gene does the drug Ranitidine Hydrochloride target? | The drug Ranitidine Hydrochloride targets the gene HRH2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ranitidine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%ranitidine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%ranitidine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1617', 'drugName': 'Ranitidine Hydrochloride', 'tradeNames_string': 'Azantac, Dumoran, Gavilast, Gavilast-p, Histac, Raciran 150, Raciran 300, Ranicalm, Raniplex, Ranitic, Ranitidine hydrochloride, Ranitil, Rantec, Ranzac, Vivatak, Zaedoc 150, Zaedoc 300, Zantac, Zantac 150, Zantac 25, Zantac 300, Zantac 75, Zantac 75 dissolve, Zantac 75 relief, Zantac 75 relief dissolve', 'drugSynonyms_string': 'AH 19065, AH-19065, Ranitidine hcl, Ranitidine hydrochloride, Taladine', 'linkedDiseasesDrug_string': 'Ulcer Disease (MONDO_0043839), Gastric Ulcer (EFO_0009454), Duodenal Ulcer (EFO_0004607), Hiv Infection (EFO_0000764)', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH2 (ENSG00000113749)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1996 | Q17 | What gene does the drug Quinapril Hydrochloride target? | The drug Quinapril Hydrochloride targets the gene ACE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%quinapril hydrochloride%" OR LOWER(tradeNames_string) LIKE "%quinapril hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%quinapril hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1269', 'drugName': 'Quinapril Hydrochloride', 'tradeNames_string': 'Accupril, Accupro, Quinapril hydrochloride, Quinil', 'drugSynonyms_string': 'CI 906, CI-906, NSC-758222, Quinapril hcl, Quinapril hydrochloride', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Stroke (EFO_0000712), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Kidney Failure (EFO_1002048)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.26 | Q17 | What gene does the drug Trimethaphan target? | The drug Trimethaphan targets 2 genes: CHRNB4 and CHRNA3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trimethaphan%" OR LOWER(tradeNames_string) LIKE "%trimethaphan%" OR LOWER(drugSynonyms_string) LIKE "%trimethaphan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4467', 'drugName': 'Trimethaphan', 'tradeNames_string': '', 'drugSynonyms_string': 'Trimetaphan, Trimethaphan, Trimethaphan cation, Trimethaphan ion', 'linkedDiseasesDrug_string': 'Insulin Resistance (EFO_0002614), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5467', 'drugName': 'Trimethaphan Camsylate', 'tradeNames_string': 'Arfonad', 'drugSynonyms_string': 'NU-2222, Trimetaphan camsilate, Trimetaphan camsylate, Trimethaphan Camsylate, Trimethaphan camphorsulfonate, Trimethaphan camsylate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1860 | Q17 | What gene does the drug Drospirenone target? | The drug Drospirenone targets 2 genes: NR3C2 and PGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%drospirenone%" OR LOWER(tradeNames_string) LIKE "%drospirenone%" OR LOWER(drugSynonyms_string) LIKE "%drospirenone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1555', 'drugName': 'Drospirenone', 'tradeNames_string': 'Angeliq, Slynd', 'drugSynonyms_string': 'Drospirenone, NSC-760103, ZK 30595, ZK-30595', 'linkedDiseasesDrug_string': 'Polycystic Ovary Syndrome (EFO_0000660), Binge Eating (EFO_0005924), Dysmenorrhea (HP_0100607), Acne (EFO_0003894), Premenstrual Tension (MONDO_0004169), Bulimia Nervosa (EFO_0005204), Depressive Disorder (MONDO_0002050), Hidradenitis Suppurativa (EFO_1000710)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175), NR3C2 (ENSG00000151623)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1556', 'drugName': 'Drospirenone', 'tradeNames_string': 'Angeliq, Slynd', 'drugSynonyms_string': 'Drospirenone, NSC-760103, ZK 30595, ZK-30595', 'linkedDiseasesDrug_string': 'Polycystic Ovary Syndrome (EFO_0000660), Binge Eating (EFO_0005924), Dysmenorrhea (HP_0100607), Acne (EFO_0003894), Premenstrual Tension (MONDO_0004169), Bulimia Nervosa (EFO_0005204), Depressive Disorder (MONDO_0002050), Hidradenitis Suppurativa (EFO_1000710)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175), NR3C2 (ENSG00000151623)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.721 | Q17 | What gene does the drug Methyltestosterone target? | The drug Methyltestosterone targets the gene AR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methyltestosterone%" OR LOWER(tradeNames_string) LIKE "%methyltestosterone%" OR LOWER(drugSynonyms_string) LIKE "%methyltestosterone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2216', 'drugName': 'Methyltestosterone', 'tradeNames_string': 'Android 10, Android 25, Android 5, Metandren, Methitest, Methyltestosterone, Oreton, Oreton methyl, Perandren, Plex hormone, Potensan fte, Testovis, Testred, Virilon', 'drugSynonyms_string': '17-methyltestosterone, CDB-110, L 589.372, L-589.372, L-589372, Methyltestosterone, Methyltestosterone ciii, NSC-139965, NSC-9701, Oxandrolone impurity, methyltestosterone-, RU 24400, RU-24400, U-2842', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Menopause (EFO_0003922), Breast Cancer (MONDO_0007254), Orchitis (EFO_1001078)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.996 | Q17 | What gene does the drug Tirzepatide target? | The drug Tirzepatide targets 2 genes: GLP1R and GIPR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tirzepatide%" OR LOWER(tradeNames_string) LIKE "%tirzepatide%" OR LOWER(drugSynonyms_string) LIKE "%tirzepatide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5134', 'drugName': 'Tirzepatide', 'tradeNames_string': 'Mounjaro', 'drugSynonyms_string': 'LY-3298176, LY3298176, Ly3298176, Mounjaro, Tirzepatide', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Obesity (EFO_0001073), Non-Alcoholic Steatohepatitis (EFO_1001249)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GIPR (ENSG00000010310), GLP1R (ENSG00000112164)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5135', 'drugName': 'Tirzepatide', 'tradeNames_string': 'Mounjaro', 'drugSynonyms_string': 'LY-3298176, LY3298176, Ly3298176, Mounjaro, Tirzepatide', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Obesity (EFO_0001073), Non-Alcoholic Steatohepatitis (EFO_1001249)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GIPR (ENSG00000010310), GLP1R (ENSG00000112164)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.196 | Q17 | What gene does the drug Pexidartinib target? | The drug Pexidartinib targets 3 genes: CSF1R, FLT3 and KIT. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pexidartinib%" OR LOWER(tradeNames_string) LIKE "%pexidartinib%" OR LOWER(drugSynonyms_string) LIKE "%pexidartinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4379', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_string': 'Turalio', 'drugSynonyms_string': 'FP-113, PLX-3397 HCL, PLX3397 HCl, Pexidartinib hydrochloride', 'linkedDiseasesDrug_string': 'Tenosynovial Giant Cell Tumor (EFO_1000562)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), FLT3 (ENSG00000122025), CSF1R (ENSG00000182578)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1793', 'drugName': 'Pexidartinib', 'tradeNames_string': '', 'drugSynonyms_string': 'CML-261, PLX-3397, PLX3397, Pexidartinib, Plx-3397', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Pigmented Villonodular Synovitis (EFO_1001106), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Giant Cell Tumor (MONDO_0002171), Tenosynovial Giant Cell Tumor (EFO_1000562), Triple-Negative Breast Cancer (EFO_0005537), Melanoma (EFO_0000756), Gastrointestinal Stromal Tumor (MONDO_0011719), Acute Myeloid Leukemia (EFO_0000222), Metastatic Melanoma (EFO_0002617), Rheumatoid Arthritis (EFO_0000685), Malignant Peripheral Nerve Sheath Tumor (EFO_0000760), Glioblastoma Multiforme (EFO_0000519), Angiosarcoma (EFO_0003968), Hodgkins Lymphoma (EFO_0000183), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), KIT (ENSG00000157404), CSF1R (ENSG00000182578)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1792', 'drugName': 'Pexidartinib', 'tradeNames_string': '', 'drugSynonyms_string': 'CML-261, PLX-3397, PLX3397, Pexidartinib, Plx-3397', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Pigmented Villonodular Synovitis (EFO_1001106), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Giant Cell Tumor (MONDO_0002171), Tenosynovial Giant Cell Tumor (EFO_1000562), Triple-Negative Breast Cancer (EFO_0005537), Melanoma (EFO_0000756), Gastrointestinal Stromal Tumor (MONDO_0011719), Acute Myeloid Leukemia (EFO_0000222), Metastatic Melanoma (EFO_0002617), Rheumatoid Arthritis (EFO_0000685), Malignant Peripheral Nerve Sheath Tumor (EFO_0000760), Glioblastoma Multiforme (EFO_0000519), Angiosarcoma (EFO_0003968), Hodgkins Lymphoma (EFO_0000183), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), KIT (ENSG00000157404), CSF1R (ENSG00000182578)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4377', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_string': 'Turalio', 'drugSynonyms_string': 'FP-113, PLX-3397 HCL, PLX3397 HCl, Pexidartinib hydrochloride', 'linkedDiseasesDrug_string': 'Tenosynovial Giant Cell Tumor (EFO_1000562)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), FLT3 (ENSG00000122025), CSF1R (ENSG00000182578)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4378', 'drugName': 'Pexidartinib Hydrochloride', 'tradeNames_string': 'Turalio', 'drugSynonyms_string': 'FP-113, PLX-3397 HCL, PLX3397 HCl, Pexidartinib hydrochloride', 'linkedDiseasesDrug_string': 'Tenosynovial Giant Cell Tumor (EFO_1000562)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KIT (ENSG00000157404), FLT3 (ENSG00000122025), CSF1R (ENSG00000182578)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1794', 'drugName': 'Pexidartinib', 'tradeNames_string': '', 'drugSynonyms_string': 'CML-261, PLX-3397, PLX3397, Pexidartinib, Plx-3397', 'linkedDiseasesDrug_string': 'Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Pigmented Villonodular Synovitis (EFO_1001106), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Giant Cell Tumor (MONDO_0002171), Tenosynovial Giant Cell Tumor (EFO_1000562), Triple-Negative Breast Cancer (EFO_0005537), Melanoma (EFO_0000756), Gastrointestinal Stromal Tumor (MONDO_0011719), Acute Myeloid Leukemia (EFO_0000222), Metastatic Melanoma (EFO_0002617), Rheumatoid Arthritis (EFO_0000685), Malignant Peripheral Nerve Sheath Tumor (EFO_0000760), Glioblastoma Multiforme (EFO_0000519), Angiosarcoma (EFO_0003968), Hodgkins Lymphoma (EFO_0000183), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), KIT (ENSG00000157404), CSF1R (ENSG00000182578)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.446 | Q17 | What gene does the drug Carprofen target? | The drug Carprofen targets the gene PTGS2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%carprofen%" OR LOWER(tradeNames_string) LIKE "%carprofen%" OR LOWER(drugSynonyms_string) LIKE "%carprofen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_354', 'drugName': 'Carprofen', 'tradeNames_string': 'Rimadyl', 'drugSynonyms_string': 'Carprofen, Carprofen for veterinary use, NSC-297935, RO 20-5720/000, Ro-205720000', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1987, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.579 | Q17 | What gene does the drug Sodelglitazar target? | The drug Sodelglitazar is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: PPARG, PPARD and PPARA | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sodelglitazar%" OR LOWER(tradeNames_string) LIKE "%sodelglitazar%" OR LOWER(drugSynonyms_string) LIKE "%sodelglitazar%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5445', 'drugName': 'Sodelglitazar', 'tradeNames_string': '', 'drugSynonyms_string': 'GW-677954, GW677954, Sodelglitazar', 'linkedDiseasesDrug_string': 'Metabolic Syndrome (EFO_0000195), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PPARA (ENSG00000186951), PPARD (ENSG00000112033)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.955 | Q17 | What gene does the drug Irinotecan Sucrosofate target? | The drug Irinotecan Sucrosofate is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TOP1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%irinotecan sucrosofate%" OR LOWER(tradeNames_string) LIKE "%irinotecan sucrosofate%" OR LOWER(drugSynonyms_string) LIKE "%irinotecan sucrosofate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2149', 'drugName': 'Irinotecan Sucrosofate', 'tradeNames_string': '', 'drugSynonyms_string': 'Irinotecan sucrosofate, MM-398, PEP-02', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TOP1 (ENSG00000198900)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.509 | Q17 | What gene does the drug Becocalcidiol target? | The drug Becocalcidiol is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene VDR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%becocalcidiol%" OR LOWER(tradeNames_string) LIKE "%becocalcidiol%" OR LOWER(drugSynonyms_string) LIKE "%becocalcidiol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5125', 'drugName': 'Becocalcidiol', 'tradeNames_string': '', 'drugSynonyms_string': '2MBisP, Becocalcidiol, DP-006, DP006, QRX 101, QRX-101, Qrx-101', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.612 | Q17 | What gene does the drug Levobupivacaine target? | The drug Levobupivacaine targets the gene SCN4A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levobupivacaine%" OR LOWER(tradeNames_string) LIKE "%levobupivacaine%" OR LOWER(drugSynonyms_string) LIKE "%levobupivacaine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4768', 'drugName': 'Levobupivacaine Hydrochloride', 'tradeNames_string': 'Chirocaine, Levobupivac', 'drugSynonyms_string': 'Bupivacaine (-)-form hydrochloride, CHIROCAINE, Levobupivacaine hcl, Levobupivacaine hydrochloride', 'linkedDiseasesDrug_string': 'Pregnancy (EFO_0002950), Pain (EFO_0003843)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN4A (ENSG00000007314)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3325', 'drugName': 'Levobupivacaine', 'tradeNames_string': '', 'drugSynonyms_string': '(-)-bupivacaine, (s)-bupivacaine, Bupivacaine (-)-form, Bupivacaine, (-)-, Bupivacaine, (s)-, L-bupivacaine, Levobupivacaine, Novabupi', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Post-Operative Sign Or Symptom (EFO_0005323), Pain (EFO_0003843), Back Pain (HP_0003418), Abdominal Pain (HP_0002027), Cleft Palate (HP_0000175), Pregnancy (EFO_0002950)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN4A (ENSG00000007314)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1864 | Q17 | What gene does the drug Remimazolam Besylate target? | The drug Remimazolam Besylate targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%remimazolam besylate%" OR LOWER(tradeNames_string) LIKE "%remimazolam besylate%" OR LOWER(drugSynonyms_string) LIKE "%remimazolam besylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1800', 'drugName': 'Remimazolam Besylate', 'tradeNames_string': 'Byfavo', 'drugSynonyms_string': 'BIPRAZINE PF, CNS 7056 besylate, CNS 7056B, CNS-7056 BESYLATE, CNS-7056B, GW-502056X, GW502056X, ONO-2745BS, ONO-IN-251, RF-10007, RF10007, Remimazolam besilate, Remimazolam besylate, SP148.5', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1725 | Q17 | What gene does the drug Atomoxetine target? | The drug Atomoxetine targets the gene SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%atomoxetine%" OR LOWER(tradeNames_string) LIKE "%atomoxetine%" OR LOWER(drugSynonyms_string) LIKE "%atomoxetine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4562', 'drugName': 'Atomoxetine', 'tradeNames_string': '', 'drugSynonyms_string': 'Atomoxetine, Strattera', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Cancer (MONDO_0004992), Alzheimer Disease (MONDO_0004975), Orthostatic Hypotension (EFO_0005252), Substance Abuse (MONDO_0002491), Tourette Syndrome (EFO_0004895), Cannabis Dependence (EFO_0007191), Nicotine Dependence (EFO_0003768), Parkinson Disease (MONDO_0005180), Attention Deficit Hyperactivity Disorder (EFO_0003888), Cocaine Dependence (EFO_0002610), Methamphetamine Dependence (EFO_0004701), Oppositional Defiant Disorder (HP_0010865), Orthostatic Intolerance (EFO_1000645), Obstructive Sleep Apnea (EFO_0003918), Social Anxiety Disorder (EFO_1001917), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Sleep Apnea (EFO_0003877), Cognitive Impairment (HP_0100543), Type 1 Diabetes Mellitus (MONDO_0005147), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1334', 'drugName': 'Atomoxetine Hydrochloride', 'tradeNames_string': 'Atomoxetine hydrochloride, Strattera', 'drugSynonyms_string': 'Atomoxetine (as hydrochloride), Atomoxetine hcl, Atomoxetine hydrochloride, LY-139603, NSC-759104, Tomoxetine, Tomoxetine hydrochloride', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Methamphetamine Dependence (EFO_0004701), Oppositional Defiant Disorder (HP_0010865), Attention Deficit Hyperactivity Disorder (EFO_0003888), Obstructive Sleep Apnea (EFO_0003918)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1885 | Q17 | What gene does the drug Larotrectinib Sulfate target? | The drug Larotrectinib Sulfate targets 3 genes: NTRK1, NTRK3 and NTRK2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%larotrectinib sulfate%" OR LOWER(tradeNames_string) LIKE "%larotrectinib sulfate%" OR LOWER(drugSynonyms_string) LIKE "%larotrectinib sulfate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3998', 'drugName': 'Larotrectinib Sulfate', 'tradeNames_string': 'Vitrakvi', 'drugSynonyms_string': 'ARRY-470 SULFATE, LOXO-101 sulfate, Larotrectinib sulfate', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Metastasis (EFO_0009708), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NTRK1 (ENSG00000198400), NTRK2 (ENSG00000148053), NTRK3 (ENSG00000140538)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.853 | Q17 | What gene does the drug Nintedanib target? | The drug Nintedanib targets 9 genes: FGFR2, FGFR3, FLT4, FGFR4, FLT1, KDR, FGFR1, PDGFRB and PDGFRA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nintedanib%" OR LOWER(tradeNames_string) LIKE "%nintedanib%" OR LOWER(drugSynonyms_string) LIKE "%nintedanib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4525', 'drugName': 'Nintedanib Esylate', 'tradeNames_string': 'Ofev', 'drugSynonyms_string': 'Nintedanib esilate, Nintedanib esylate, Nintedanib ethanesulfonate', 'linkedDiseasesDrug_string': 'Idiopathic Pulmonary Fibrosis (EFO_0000768), Systemic Scleroderma (EFO_0000717)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_5929', 'drugName': 'Nintedanib', 'tradeNames_string': 'Ofev, Vargatef', 'drugSynonyms_string': 'BIBF 1120, BIBF-1120, BIBF1120, Bibf-1120, Intedanib, Nintedanib', 'linkedDiseasesDrug_string': 'Genital Neoplasm, Female (EFO_1001331), Multiple Myeloma (EFO_0001378), Covid-19 (MONDO_0100096), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Appendix Cancer (MONDO_0001235), Squamous Cell Lung Carcinoma (EFO_0000708), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Idiopathic Pulmonary Fibrosis (EFO_0000768), Endometrial Cancer (MONDO_0011962), Rectal Carcinoma (MONDO_0044937), Colorectal Carcinoma (EFO_1001951), Bronchiolitis Obliterans (EFO_0007183), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Cervical Adenocarcinoma (EFO_0001416), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Lymphangioleiomyomatosis (MONDO_0011705), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Interstitial Lung Disease (EFO_0004244), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Malignant Pleural Mesothelioma (EFO_0000770), Sarcoma (EFO_0000691), Colon Adenocarcinoma (EFO_1001949), Pulmonary Fibrosis (EFO_0009448), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_5928', 'drugName': 'Nintedanib', 'tradeNames_string': 'Ofev, Vargatef', 'drugSynonyms_string': 'BIBF 1120, BIBF-1120, BIBF1120, Bibf-1120, Intedanib, Nintedanib', 'linkedDiseasesDrug_string': 'Genital Neoplasm, Female (EFO_1001331), Multiple Myeloma (EFO_0001378), Covid-19 (MONDO_0100096), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Appendix Cancer (MONDO_0001235), Squamous Cell Lung Carcinoma (EFO_0000708), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Idiopathic Pulmonary Fibrosis (EFO_0000768), Endometrial Cancer (MONDO_0011962), Rectal Carcinoma (MONDO_0044937), Colorectal Carcinoma (EFO_1001951), Bronchiolitis Obliterans (EFO_0007183), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Cervical Adenocarcinoma (EFO_0001416), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Lymphangioleiomyomatosis (MONDO_0011705), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Interstitial Lung Disease (EFO_0004244), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Malignant Pleural Mesothelioma (EFO_0000770), Sarcoma (EFO_0000691), Colon Adenocarcinoma (EFO_1001949), Pulmonary Fibrosis (EFO_0009448), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_4523', 'drugName': 'Nintedanib Esylate', 'tradeNames_string': 'Ofev', 'drugSynonyms_string': 'Nintedanib esilate, Nintedanib esylate, Nintedanib ethanesulfonate', 'linkedDiseasesDrug_string': 'Idiopathic Pulmonary Fibrosis (EFO_0000768), Systemic Scleroderma (EFO_0000717)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_4524', 'drugName': 'Nintedanib Esylate', 'tradeNames_string': 'Ofev', 'drugSynonyms_string': 'Nintedanib esilate, Nintedanib esylate, Nintedanib ethanesulfonate', 'linkedDiseasesDrug_string': 'Idiopathic Pulmonary Fibrosis (EFO_0000768), Systemic Scleroderma (EFO_0000717)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_5930', 'drugName': 'Nintedanib', 'tradeNames_string': 'Ofev, Vargatef', 'drugSynonyms_string': 'BIBF 1120, BIBF-1120, BIBF1120, Bibf-1120, Intedanib, Nintedanib', 'linkedDiseasesDrug_string': 'Genital Neoplasm, Female (EFO_1001331), Multiple Myeloma (EFO_0001378), Covid-19 (MONDO_0100096), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Appendix Cancer (MONDO_0001235), Squamous Cell Lung Carcinoma (EFO_0000708), Hereditary Hemorrhagic Telangiectasia (MONDO_0019180), Idiopathic Pulmonary Fibrosis (EFO_0000768), Endometrial Cancer (MONDO_0011962), Rectal Carcinoma (MONDO_0044937), Colorectal Carcinoma (EFO_1001951), Bronchiolitis Obliterans (EFO_0007183), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Cervical Adenocarcinoma (EFO_0001416), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Lymphangioleiomyomatosis (MONDO_0011705), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Interstitial Lung Disease (EFO_0004244), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Malignant Pleural Mesothelioma (EFO_0000770), Sarcoma (EFO_0000691), Colon Adenocarcinoma (EFO_1001949), Pulmonary Fibrosis (EFO_0009448), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052)', 'numberLinkedTargets': 9}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.4 | Q17 | What gene does the drug Dipivefrin Hydrochloride target? | The drug Dipivefrin Hydrochloride targets 9 genes: ADRA2A, ADRB1, ADRA2C, ADRA1A, ADRA1D, ADRA1B, ADRB3, ADRA2B and ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dipivefrin hydrochloride%" OR LOWER(tradeNames_string) LIKE "%dipivefrin hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%dipivefrin hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1692', 'drugName': 'Dipivefrin Hydrochloride', 'tradeNames_string': 'Akpro, Dipivefrin hydrochloride, Propine', 'drugSynonyms_string': 'Dipivefrin hcl, Dipivefrin hydrochloride, Dipivefrine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 9}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1569 | Q17 | What gene does the drug Nortriptyline Hydrochloride target? | The drug Nortriptyline Hydrochloride targets 2 genes: SLC6A4 and SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nortriptyline hydrochloride%" OR LOWER(tradeNames_string) LIKE "%nortriptyline hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%nortriptyline hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5991', 'drugName': 'Nortriptyline Hydrochloride', 'tradeNames_string': 'Aventyl, Aventyl hydrochloride, Nortriptyline hydrochloride, Pamelor, Psychostyl', 'drugSynonyms_string': '38489, NSC-169453, Nortriptyline hcl, Nortriptyline hydrochloride', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Unipolar Depression (EFO_0003761), Small Cell Carcinoma (EFO_0008524), Atopic Eczema (EFO_0000274), Gastroparesis (EFO_1000948)', 'yearOfFirstApproval': 1964, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5992', 'drugName': 'Nortriptyline Hydrochloride', 'tradeNames_string': 'Aventyl, Aventyl hydrochloride, Nortriptyline hydrochloride, Pamelor, Psychostyl', 'drugSynonyms_string': '38489, NSC-169453, Nortriptyline hcl, Nortriptyline hydrochloride', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Unipolar Depression (EFO_0003761), Small Cell Carcinoma (EFO_0008524), Atopic Eczema (EFO_0000274), Gastroparesis (EFO_1000948)', 'yearOfFirstApproval': 1964, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1461 | Q17 | What gene does the drug Alprostadil target? | The drug Alprostadil targets 2 genes: PTGER2 and PTGER1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alprostadil%" OR LOWER(tradeNames_string) LIKE "%alprostadil%" OR LOWER(drugSynonyms_string) LIKE "%alprostadil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4035', 'drugName': 'Alprostadil', 'tradeNames_string': 'Alprostadil, Caverject, Caverject impulse, Edex, Prostin, Prostin vr, Prostin vr pediatric, Viridal 10, Viridal 20, Viridal 5, Viridal duo, Vitaros', 'drugSynonyms_string': 'Alprostadil, NSC-165559, ONO-1608, Pge1, Prostaglandin e1, U-10,136, U-10136', 'linkedDiseasesDrug_string': 'Erectile Dysfunction (EFO_0004234), Macular Degeneration (EFO_0009606), Prostate Cancer (MONDO_0008315), Arteriosclerosis Obliterans (EFO_1000820), Peripheral Arterial Disease (EFO_0004265), Heart Failure (EFO_0003144), Covid-19 (MONDO_0100096), Cardiovascular Disease (EFO_0000319), Peripheral Vascular Disease (EFO_0003875), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Acute Kidney Injury (HP_0001919), Patent Ductus Arteriosus (HP_0001643), Sexual Dysfunction (EFO_0004714), Anterior Ischemic Optic Neuropathy (EFO_1000809)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGER2 (ENSG00000125384), PTGER1 (ENSG00000160951)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4036', 'drugName': 'Alprostadil', 'tradeNames_string': 'Alprostadil, Caverject, Caverject impulse, Edex, Prostin, Prostin vr, Prostin vr pediatric, Viridal 10, Viridal 20, Viridal 5, Viridal duo, Vitaros', 'drugSynonyms_string': 'Alprostadil, NSC-165559, ONO-1608, Pge1, Prostaglandin e1, U-10,136, U-10136', 'linkedDiseasesDrug_string': 'Erectile Dysfunction (EFO_0004234), Macular Degeneration (EFO_0009606), Prostate Cancer (MONDO_0008315), Arteriosclerosis Obliterans (EFO_1000820), Peripheral Arterial Disease (EFO_0004265), Heart Failure (EFO_0003144), Covid-19 (MONDO_0100096), Cardiovascular Disease (EFO_0000319), Peripheral Vascular Disease (EFO_0003875), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Acute Kidney Injury (HP_0001919), Patent Ductus Arteriosus (HP_0001643), Sexual Dysfunction (EFO_0004714), Anterior Ischemic Optic Neuropathy (EFO_1000809)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGER2 (ENSG00000125384), PTGER1 (ENSG00000160951)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.473 | Q17 | What gene does the drug Anastrozole target? | The drug Anastrozole targets the gene CYP19A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%anastrozole%" OR LOWER(tradeNames_string) LIKE "%anastrozole%" OR LOWER(drugSynonyms_string) LIKE "%anastrozole%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3640', 'drugName': 'Anastrozole', 'tradeNames_string': 'Anastrozole, Arimidex, Nastrosa', 'drugSynonyms_string': 'Anastrozole, Arimidex, ICI D1033, ICI-D1033, NSC-719344, NSC-759855, Rvg-106400, ZD-1033, ZD1033', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Pulmonary Arterial Hypertension (EFO_0001361), Peritoneal Neoplasm (EFO_1001100), Mccune-Albright Syndrome (MONDO_0018919), Aging (GO_0007568), Endometrial Cancer (MONDO_0011962), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Hypertension (EFO_0000537), Male Breast Carcinoma (EFO_0006861), Endometriosis (EFO_0001065), Anovulation (MONDO_0002775), Endometrial Carcinoma (EFO_1001512), Hypogonadism (MONDO_0002146), Triple-Negative Breast Cancer (EFO_0005537), Hypopituitarism (EFO_0001380), Carcinoma (EFO_0000313), Breast Ductal Carcinoma In Situ (EFO_0000432), Precocious Puberty (MONDO_0000088), Invasive Lobular Carcinoma (EFO_0000553), Kallmann Syndrome (MONDO_0018800), Neoplasm (EFO_0000616), Gynecomastia (HP_0000771), Metabolic Syndrome (EFO_0000195)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP19A1 (ENSG00000137869)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.325 | Q17 | What gene does the drug Inotuzumab Ozogamicin target? | The drug Inotuzumab Ozogamicin targets the gene CD22. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%inotuzumab ozogamicin%" OR LOWER(tradeNames_string) LIKE "%inotuzumab ozogamicin%" OR LOWER(drugSynonyms_string) LIKE "%inotuzumab ozogamicin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6318', 'drugName': 'Inotuzumab Ozogamicin', 'tradeNames_string': 'Besponsa', 'drugSynonyms_string': 'CMC-544, Inotuzumab ozogamicin, PF-05208773, WAY-207294, WAY-207294 CMC-544', 'linkedDiseasesDrug_string': 'Non-Hodgkins Lymphoma (EFO_0005952), Follicular Lymphoma (MONDO_0018906), Neoplasm (EFO_0000616), Neoplasm Of Mature B-Cells (EFO_0000096), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoblastic Lymphoma (MONDO_0000873), Lymphoma (EFO_0000574), Burkitts Lymphoma (EFO_0000309), Diffuse Large B-Cell Lymphoma (EFO_0000403), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD22 (ENSG00000012124)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.6 | Q17 | What gene does the drug Trimipramine Maleate target? | The drug Trimipramine Maleate targets 8 genes: SLC6A2, ADRA1A, HTR2A, HRH1, ADRA1D, DRD2, HTR2C and ADRA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trimipramine maleate%" OR LOWER(tradeNames_string) LIKE "%trimipramine maleate%" OR LOWER(drugSynonyms_string) LIKE "%trimipramine maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_609', 'drugName': 'Trimipramine Maleate', 'tradeNames_string': 'Surmontil, Trimipramine maleate', 'drugSynonyms_string': 'NSC-758386, Stangyl, Trimipramine maleate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HRH1 (ENSG00000196639)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_611', 'drugName': 'Trimipramine Maleate', 'tradeNames_string': 'Surmontil, Trimipramine maleate', 'drugSynonyms_string': 'NSC-758386, Stangyl, Trimipramine maleate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HRH1 (ENSG00000196639)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_607', 'drugName': 'Trimipramine Maleate', 'tradeNames_string': 'Surmontil, Trimipramine maleate', 'drugSynonyms_string': 'NSC-758386, Stangyl, Trimipramine maleate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HRH1 (ENSG00000196639)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_839', 'drugName': 'Imipramine', 'tradeNames_string': '', 'drugSynonyms_string': 'Antideprin, Berkomine, Cristalia, Imipramine, Janimine, Melipramine, NSC-169866, ORG-2463, Pramine, Presamine, Sermonil, Tofranil, Tofranil-PM, Trimipramine maleate impurity, imipramine-', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Breast Cancer (MONDO_0007254), Somatoform Disorder (EFO_0009687), Enuresis (MONDO_0024290), Ventricular Fibrillation (EFO_0004287), Dementia (HP_0000726), Myocardial Infarction (EFO_0000612), Anxiety (EFO_0005230), Sudden Cardiac Arrest (EFO_0004278), Dysthymic Disorder (EFO_0008623), Chest Pain (HP_0100749), Depressive Disorder (MONDO_0002050), Glioblastoma Multiforme (EFO_0000519), Low Back Pain (HP_0003419), Schizophrenia (MONDO_0005090), Gastroesophageal Reflux Disease (EFO_0003948), Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_838', 'drugName': 'Imipramine', 'tradeNames_string': '', 'drugSynonyms_string': 'Antideprin, Berkomine, Cristalia, Imipramine, Janimine, Melipramine, NSC-169866, ORG-2463, Pramine, Presamine, Sermonil, Tofranil, Tofranil-PM, Trimipramine maleate impurity, imipramine-', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Breast Cancer (MONDO_0007254), Somatoform Disorder (EFO_0009687), Enuresis (MONDO_0024290), Ventricular Fibrillation (EFO_0004287), Dementia (HP_0000726), Myocardial Infarction (EFO_0000612), Anxiety (EFO_0005230), Sudden Cardiac Arrest (EFO_0004278), Dysthymic Disorder (EFO_0008623), Chest Pain (HP_0100749), Depressive Disorder (MONDO_0002050), Glioblastoma Multiforme (EFO_0000519), Low Back Pain (HP_0003419), Schizophrenia (MONDO_0005090), Gastroesophageal Reflux Disease (EFO_0003948), Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_610', 'drugName': 'Trimipramine Maleate', 'tradeNames_string': 'Surmontil, Trimipramine maleate', 'drugSynonyms_string': 'NSC-758386, Stangyl, Trimipramine maleate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HRH1 (ENSG00000196639)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_608', 'drugName': 'Trimipramine Maleate', 'tradeNames_string': 'Surmontil, Trimipramine maleate', 'drugSynonyms_string': 'NSC-758386, Stangyl, Trimipramine maleate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HRH1 (ENSG00000196639)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_606', 'drugName': 'Trimipramine Maleate', 'tradeNames_string': 'Surmontil, Trimipramine maleate', 'drugSynonyms_string': 'NSC-758386, Stangyl, Trimipramine maleate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HRH1 (ENSG00000196639)', 'numberLinkedTargets': 8}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.225 | Q17 | What gene does the drug Jnj-18038683 target? | The drug Jnj-18038683 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene HTR7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%jnj-18038683%" OR LOWER(tradeNames_string) LIKE "%jnj-18038683%" OR LOWER(drugSynonyms_string) LIKE "%jnj-18038683%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_696', 'drugName': 'Jnj-18038683', 'tradeNames_string': '', 'drugSynonyms_string': 'Jnj-18038683', 'linkedDiseasesDrug_string': 'Major Depressive Disorder (MONDO_0002009), Bipolar Disorder (MONDO_0004985)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR7 (ENSG00000148680)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3822', 'drugName': 'Jnj-18038683', 'tradeNames_string': '', 'drugSynonyms_string': '', 'linkedDiseasesDrug_string': 'Major Depressive Disorder (MONDO_0002009), Bipolar Disorder (MONDO_0004985)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR7 (ENSG00000148680)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1376 | Q17 | What gene does the drug Proxibarbal target? | The drug Proxibarbal targets 2 genes: MAOA and AOC1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%proxibarbal%" OR LOWER(tradeNames_string) LIKE "%proxibarbal%" OR LOWER(drugSynonyms_string) LIKE "%proxibarbal%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_472', 'drugName': 'Proxibarbal', 'tradeNames_string': '', 'drugSynonyms_string': 'Axeen, Centralgol, HH-184, Hydroxydial, Ipronal, Proxibarbal', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AOC1 (ENSG00000002726), MAOA (ENSG00000189221)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_473', 'drugName': 'Proxibarbal', 'tradeNames_string': '', 'drugSynonyms_string': 'Axeen, Centralgol, HH-184, Hydroxydial, Ipronal, Proxibarbal', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AOC1 (ENSG00000002726), MAOA (ENSG00000189221)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.553 | Q17 | What gene does the drug Drotrecogin Alfa (Activated) target? | The drug Drotrecogin Alfa (Activated) targets 2 genes: F8 and F5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%drotrecogin alfa (activated)%" OR LOWER(tradeNames_string) LIKE "%drotrecogin alfa (activated)%" OR LOWER(drugSynonyms_string) LIKE "%drotrecogin alfa (activated)%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2502', 'drugName': 'Drotrecogin Alfa (Activated)', 'tradeNames_string': 'Xigris', 'drugSynonyms_string': 'Activated protein c, Drotrecogin alfa, Drotrecogin alfa (activated), Drotrecogin alfa activated, Drotrecogin alfa, activated, Drotrecogin-alfa, LY-203638, LY203638', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Chronic Kidney Disease (EFO_0003884), Sepsis (HP_0100806), Ischemic Stroke (HP_0002140), Septic Shock (EFO_0006834), Stroke (EFO_0000712), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Pulmonary Embolism (EFO_0003827), Hypotension (EFO_0005251)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'F8 (ENSG00000185010), F5 (ENSG00000198734)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2503', 'drugName': 'Drotrecogin Alfa (Activated)', 'tradeNames_string': 'Xigris', 'drugSynonyms_string': 'Activated protein c, Drotrecogin alfa, Drotrecogin alfa (activated), Drotrecogin alfa activated, Drotrecogin alfa, activated, Drotrecogin-alfa, LY-203638, LY203638', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Chronic Kidney Disease (EFO_0003884), Sepsis (HP_0100806), Ischemic Stroke (HP_0002140), Septic Shock (EFO_0006834), Stroke (EFO_0000712), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Pulmonary Embolism (EFO_0003827), Hypotension (EFO_0005251)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'F8 (ENSG00000185010), F5 (ENSG00000198734)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.231 | Q17 | What gene does the drug Hokt3 target? | The drug Hokt3 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD3E. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hokt3%" OR LOWER(tradeNames_string) LIKE "%hokt3%" OR LOWER(drugSynonyms_string) LIKE "%hokt3%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4396', 'drugName': 'Hokt3', 'tradeNames_string': '', 'drugSynonyms_string': 'HOKT3, Hokt3', 'linkedDiseasesDrug_string': 'Psoriatic Arthritis (EFO_0003778), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD3E (ENSG00000198851)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3514', 'drugName': 'Teplizumab', 'tradeNames_string': '', 'drugSynonyms_string': 'HOKT3-GAMMA-1 (ALA-ALA), HUMANIZED OKT3, Humanzied OKT3, MGA-031, MGA031, Teplizumab, hOKT3 gamma 1 (Ala-Ala)', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Abnormal Glucose Tolerance (EFO_0002546), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD3E (ENSG00000198851)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.40 | Q17 | What gene does the drug Interferon Alfacon-1 target? | The drug Interferon Alfacon-1 targets 2 genes: IFNAR1 and IFNAR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%interferon alfacon-1%" OR LOWER(tradeNames_string) LIKE "%interferon alfacon-1%" OR LOWER(drugSynonyms_string) LIKE "%interferon alfacon-1%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4051', 'drugName': 'Interferon Alfacon-1', 'tradeNames_string': 'Infergen', 'drugSynonyms_string': 'Interferon alfacon-1, Rsifn-co', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Covid-19 (MONDO_0100096), Chronic Hepatitis C Virus Infection (EFO_0004220), Influenza (EFO_0007328), Hepatitis C Virus Infection (EFO_0003047)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IFNAR1 (ENSG00000142166), IFNAR2 (ENSG00000159110)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.548 | Q17 | What gene does the drug Birinapant target? | The drug Birinapant is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: BIRC3 and BIRC2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%birinapant%" OR LOWER(tradeNames_string) LIKE "%birinapant%" OR LOWER(drugSynonyms_string) LIKE "%birinapant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_267', 'drugName': 'Birinapant', 'tradeNames_string': '', 'drugSynonyms_string': 'Birinapant, TL-32711, TL32711', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Fallopian Tube Carcinoma (EFO_1000251), Fallopian Tube Cancer (MONDO_0002158), Hepatitis B Virus Infection (EFO_0004197), Neoplasm (EFO_0000616), Peritoneal Neoplasm (EFO_1001100), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Myelodysplastic Syndrome (EFO_0000198), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'BIRC3 (ENSG00000023445), BIRC2 (ENSG00000110330)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.245 | Q17 | What gene does the drug Insulin Zinc Susp Purified Beef target? | The drug Insulin Zinc Susp Purified Beef targets the gene INSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%insulin zinc susp purified beef%" OR LOWER(tradeNames_string) LIKE "%insulin zinc susp purified beef%" OR LOWER(drugSynonyms_string) LIKE "%insulin zinc susp purified beef%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2997', 'drugName': 'Insulin Zinc Susp Purified Beef', 'tradeNames_string': 'Lente iletin ii', 'drugSynonyms_string': 'Insulin zinc susp purified beef', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2821', 'drugName': 'Insulin Zinc Susp Purified Beef/Pork', 'tradeNames_string': 'Lentard', 'drugSynonyms_string': 'Insulin zinc susp purified beef/pork', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.905 | Q17 | What gene does the drug Tenapanor Hydrochloride target? | The drug Tenapanor Hydrochloride targets the gene SLC9A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tenapanor hydrochloride%" OR LOWER(tradeNames_string) LIKE "%tenapanor hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%tenapanor hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3816', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_string': 'Ibsrela', 'drugSynonyms_string': 'AZD-1722 HYDROCHLORIDE, AZD1722, AZD1722 hydrochloride, RDX-5791, RDX5791, Tenapanor dihydrochloride, Tenapanor hydrochloride', 'linkedDiseasesDrug_string': 'Irritable Bowel Syndrome (EFO_0000555), Constipation Disorder (MONDO_0002203), Chronic Kidney Disease (EFO_0003884), Hyperphosphatemia (HP_0002905)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC9A3 (ENSG00000066230)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1429 | Q17 | What gene does the drug Phenoxybenzamine Hydrochloride target? | The drug Phenoxybenzamine Hydrochloride targets 6 genes: ADRA2A, ADRA2C, ADRA1A, ADRA1D, ADRA2B and ADRA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%phenoxybenzamine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%phenoxybenzamine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%phenoxybenzamine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1879', 'drugName': 'Phenoxybenzamine Hydrochloride', 'tradeNames_string': 'Dibenyline, Dibenzyline, Phenoxybenzamine hydrochloride', 'drugSynonyms_string': 'Bensylyte hydrochloride, Dibenzylin, Dibenzyline chloride, Dibenzyline hydrochloride, Dibenzyran, NSC-37448, Phenoxybenzamine chloride, Phenoxybenzamine hcl, Phenoxybenzamine hydrochloride', 'linkedDiseasesDrug_string': 'Adrenal Gland Pheochromocytoma (EFO_0000239)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.139 | Q17 | What gene does the drug Pf-04236921 target? | The drug Pf-04236921 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IL6. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pf-04236921%" OR LOWER(tradeNames_string) LIKE "%pf-04236921%" OR LOWER(drugSynonyms_string) LIKE "%pf-04236921%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4784', 'drugName': 'Pf-04236921', 'tradeNames_string': '', 'drugSynonyms_string': 'PF 4236921, PF-04236921, PF-4236921, Pf-04236921', 'linkedDiseasesDrug_string': "Systemic Lupus Erythematosus (MONDO_0007915), Crohn'S Disease (EFO_0000384)", 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL6 (ENSG00000136244)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1191 | Q17 | What gene does the drug Cilomilast target? | The drug Cilomilast is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 4 genes: PDE4A, PDE4D, PDE4B and PDE4C | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cilomilast%" OR LOWER(tradeNames_string) LIKE "%cilomilast%" OR LOWER(drugSynonyms_string) LIKE "%cilomilast%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4417', 'drugName': 'Cilomilast', 'tradeNames_string': '', 'drugSynonyms_string': 'Ariflo, Cilomilast, SB 207499, SB-207499', 'linkedDiseasesDrug_string': 'Chronic Obstructive Pulmonary Disease (EFO_0000341)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1757 | Q17 | What gene does the drug Ibutamoren target? | The drug Ibutamoren is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene GHSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ibutamoren%" OR LOWER(tradeNames_string) LIKE "%ibutamoren%" OR LOWER(drugSynonyms_string) LIKE "%ibutamoren%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1333', 'drugName': 'Ibutamoren', 'tradeNames_string': '', 'drugSynonyms_string': 'Ibutamoren, L-163,191, MK-677', 'linkedDiseasesDrug_string': 'Aging (GO_0007568), Fibromyalgia (EFO_0005687)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GHSR (ENSG00000121853)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2142', 'drugName': 'Ibutamoren Mesylate', 'tradeNames_string': '', 'drugSynonyms_string': 'Ibutamoren mesilate, Ibutamoren mesylate, MK-0677, MK-677', 'linkedDiseasesDrug_string': 'Fibromyalgia (EFO_0005687)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GHSR (ENSG00000121853)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1573 | Q17 | What gene does the drug Insulin target? | The drug Insulin targets the gene INSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%insulin%" OR LOWER(tradeNames_string) LIKE "%insulin%" OR LOWER(drugSynonyms_string) LIKE "%insulin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_495', 'drugName': 'Insulin Glargine', 'tradeNames_string': 'Abasaglar, Abasaglar kwikpen, Basaglar, Ins lantus, Ins lantus opticlik, Ins lantus optiset, Ins lantus solostar, Lantus, Lantus solostar, Toujeo, Toujeo max solostar, Toujeo solostar', 'drugSynonyms_string': 'Basalin, Basalog, Galactus, Glargin, Glargine, Glaricon, HOE 71GT, HOE 901, HOE-71GT, HOE-901, Insulin Glargine Recombinant, Insulin glargine, Insulin glargine recombinant, Insulin glargine yfgn, Insulin glargine-yfgn, LY-2963016, LY2963016, Lantus r, Lusduna, MK-1293, MYL-1501D, Myl-1501d, Semglee', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperglycemia (HP_0003074), Coronary Artery Disease (EFO_0001645), Diabetic Ketoacidosis (EFO_1000897), Leukemia (EFO_0000565), Diabetic Retinopathy (EFO_0003770), Hypertension (EFO_0000537), Lymphoma (EFO_0000574), Hypercholesterolemia (HP_0003124), Myocardial Infarction (EFO_0000612), Prediabetes Syndrome (EFO_1001121), Cystic Fibrosis (MONDO_0009061), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5706', 'drugName': 'Insulin Susp Isophane Beef', 'tradeNames_string': 'Nph insulin', 'drugSynonyms_string': 'Insulin susp isophane beef', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Gestational Diabetes (EFO_0004593), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_578', 'drugName': 'Insulin Lispro', 'tradeNames_string': 'Admelog, Admelog solostar, Humalog, Humalog kwikpen, Humalog pen, Humalog tempo pen, Ins humalog', 'drugSynonyms_string': 'Insulin Lispro Recombinant, Insulin lispro, Insulin lispro recombinant, Lyumjev', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148), Hyperglycemia (HP_0003074), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5121', 'drugName': 'Insulin Lispro Protamine Recombinant', 'tradeNames_string': '', 'drugSynonyms_string': 'Insulin lispro protamine recombinant', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4915', 'drugName': 'Insulin Susp Isophane Recombinant Human', 'tradeNames_string': 'Humulin n, Novolin n', 'drugSynonyms_string': 'Insulin susp isophane recombinant human', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperglycemia (HP_0003074), Coronary Artery Disease (EFO_0001645), Hypertension (EFO_0000537), Hypercholesterolemia (HP_0003124), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5849', 'drugName': 'Insulin Susp Isophane Semisynthetic Purified Human', 'tradeNames_string': 'Insulatard nph human, Novolin n', 'drugSynonyms_string': 'Insulin susp isophane semisynthetic purified human', 'linkedDiseasesDrug_string': 'Hyperglycemia (HP_0003074), Coronary Artery Disease (EFO_0001645), Hypertension (EFO_0000537), Hypercholesterolemia (HP_0003124), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4168', 'drugName': 'Insulin Detemir', 'tradeNames_string': 'Ins levemir, Levemir, Levemir flexpen, Levemir flextouch, Levemir innolet, Levemir penfill', 'drugSynonyms_string': 'Detemir, Insulin detemir, Insulin detemir recombinant, Insulin,detemir,human, NN-304', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Hypertension (EFO_0000537), Hypercholesterolemia (HP_0003124), Cystic Fibrosis (MONDO_0009061), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3685', 'drugName': 'Insulin Degludec', 'tradeNames_string': 'Ins tresiba, Tresiba', 'drugSynonyms_string': 'Insulin degludec, NN-1250, NN1250', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1693', 'drugName': 'Insulin Susp Isophane Beef/Pork', 'tradeNames_string': 'Nph iletin i (beef-pork)', 'drugSynonyms_string': 'Insulin susp isophane beef/pork', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1966, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2164', 'drugName': 'Insulin Susp Protamine Zinc Beef/Pork', 'tradeNames_string': 'Protamine zinc & iletin i (beef-pork)', 'drugSynonyms_string': 'Insulin susp protamine zinc beef/pork', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1966, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1882', 'drugName': 'Insulin Purified Pork', 'tradeNames_string': 'Iletin ii, Regular iletin ii (pork), Regular purified pork insulin, Velosulin', 'drugSynonyms_string': 'Insulin (pork), Insulin purified pork', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3326', 'drugName': 'Insulin Susp Isophane Purified Pork', 'tradeNames_string': 'Insulin insulatard nph nordisk, Nph iletin ii (pork), Nph purified pork isophane insulin', 'drugSynonyms_string': 'Insulin susp isophane purified pork', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5559', 'drugName': 'Insulin Susp Protamine Zinc Purified Pork', 'tradeNames_string': 'Protamine zinc and iletin ii (pork)', 'drugSynonyms_string': 'Insulin susp protamine zinc purified pork', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4979', 'drugName': 'Insulin Aspart', 'tradeNames_string': 'Fiasp, Fiasp flextouch, Fiasp penfill, Ins novorapid, Novolog, Novolog flexpen, Novolog flextouch, Novolog innolet, Novolog penfill', 'drugSynonyms_string': 'B28-ASP-INSULIN, INA-X14, INSULIN X14, Insulin aspart, Insulin aspart recombinant', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Alzheimer Disease (MONDO_0004975), Coronary Artery Disease (EFO_0001645), Leukemia (EFO_0000565), Hypertension (EFO_0000537), Lymphoma (EFO_0000574), Gestational Diabetes (EFO_0004593), Hypercholesterolemia (HP_0003124), Cystic Fibrosis (MONDO_0009061), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2997', 'drugName': 'Insulin Zinc Susp Purified Beef', 'tradeNames_string': 'Lente iletin ii', 'drugSynonyms_string': 'Insulin zinc susp purified beef', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3637', 'drugName': 'Insulin Susp Protamine Zinc Purified Beef', 'tradeNames_string': 'Protamine zinc and iletin ii, Protamine zinc insulin', 'drugSynonyms_string': 'Insulin susp protamine zinc purified beef', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4804', 'drugName': 'Insulin Susp Isophane Purified Beef', 'tradeNames_string': 'Nph iletin ii', 'drugSynonyms_string': 'Insulin susp isophane purified beef', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_496', 'drugName': 'Insulin Zinc Susp Beef', 'tradeNames_string': 'Lente insulin', 'drugSynonyms_string': 'Insulin zinc susp beef', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_994', 'drugName': 'Insulin Zinc Susp Extended Purified Beef', 'tradeNames_string': 'Ultralente', 'drugSynonyms_string': 'Insulin zinc susp extended purified beef', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1271', 'drugName': 'Insulin Zinc Susp Prompt Purified Pork', 'tradeNames_string': 'Semilente', 'drugSynonyms_string': 'Insulin zinc susp prompt purified pork', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1883', 'drugName': 'Insulin Zinc Susp Extended Beef', 'tradeNames_string': 'Ultralente insulin', 'drugSynonyms_string': 'Insulin zinc susp extended beef', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3871', 'drugName': 'Insulin Zinc Susp Prompt Beef', 'tradeNames_string': 'Semilente insulin', 'drugSynonyms_string': 'Insulin zinc susp prompt beef', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5848', 'drugName': 'Insulin Zinc Susp Semisynthetic Purified Human', 'tradeNames_string': 'Novolin l', 'drugSynonyms_string': 'Insulin zinc susp semisynthetic purified human', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5348', 'drugName': 'Insulin Zinc Susp Recombinant Human', 'tradeNames_string': 'Humulin l, Novolin l', 'drugSynonyms_string': 'Insulin zinc susp recombinant human', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4713', 'drugName': 'Insulin Zinc Susp Extended Recombinant Human', 'tradeNames_string': 'Humulin u', 'drugSynonyms_string': 'Insulin zinc susp extended recombinant human', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1987, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1048', 'drugName': 'Insulin Aspart Protamine Recombinant', 'tradeNames_string': '', 'drugSynonyms_string': 'Insulin aspart protamine recombinant', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3610', 'drugName': 'Insulin Zinc, Prompt', 'tradeNames_string': 'Ins semit mc, Semilente, Semilente iletin', 'drugSynonyms_string': 'Amorphous (aqueous suspension), Insulin zinc injection, Insulin zinc injection, amorphous (aqueous suspension), Insulin zinc suspension , Insulin zinc suspension (amorphous), Insulin zinc, prompt', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4870', 'drugName': 'Insulin [Injection], Biphasic', 'tradeNames_string': 'Ins rapit mc', 'drugSynonyms_string': 'Biphasic insulin injection, Insulin [injection], biphasic', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2821', 'drugName': 'Insulin Zinc Susp Purified Beef/Pork', 'tradeNames_string': 'Lentard', 'drugSynonyms_string': 'Insulin zinc susp purified beef/pork', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2750', 'drugName': 'Mecasermin', 'tradeNames_string': 'Increlex, Myotrophin', 'drugSynonyms_string': 'CEP-151, Cg-gf2, Cg-igf-1, Igf-1-ec, Igf-1ec, Insulin-like growth factor 1, Insulin-like growth factor i, Mecasermin, Mecasermin recombinant, Mechano growth factor, Pv-802, Pv802, Rh-oligopeptide-2, Sh-oligopeptide-2, Somatomedin c, Somatomedin c, human, Vexxon-igf-1', 'linkedDiseasesDrug_string': "Diabetes Mellitus (EFO_0000400), Bone Disease (EFO_0004260), Growth Hormone Insensitivity Syndrome (MONDO_0015892), Tendinopathy (EFO_1001434), Crohn'S Disease (EFO_0000384), Growth Delay (HP_0001510), Amyotrophic Lateral Sclerosis (MONDO_0004976), Multiple Sclerosis (MONDO_0005301), Noonan Syndrome (MONDO_0018997), Hiv-Associated Lipodystrophy Syndrome (EFO_1001348), Rett Syndrome (MONDO_0010726), Aging (GO_0007568), Anorexia Nervosa (MONDO_0005351), Hypothyroidism (EFO_0004705), Hyperinsulinism (MONDO_0002177), Retinopathy Of Prematurity (EFO_1001158)", 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2549', 'drugName': 'Insulin', 'tradeNames_string': 'Afrezza, Exubera, Humulin, Humulin br, Humulin r, Humulin r kwikpen, Humulin r pen, Ins humulin r, Insuman infusat, Myxredlin, Novolin, Novolin r, Velosulin, Velosulin br, Velosulin br human', 'drugSynonyms_string': 'INSULIN BOVINE INSULIN, Insulin, Insulin (human), Insulin Recombinant Human, Insulin bovine, Insulin human, Insulin human (biosynthesis), Insulin human (synthesis), Insulin human semisynthetic, Insulin recombinant human, Insulin recombinant purified human', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Coronary Artery Disease (EFO_0001645), Carpal Tunnel Syndrome (EFO_0004143), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Dry Eye Syndrome (EFO_1000906), Hypogonadotropic Hypogonadism (MONDO_0018555), Injury (EFO_0000546), Glaucoma (MONDO_0005041), Hypoglycemia (HP_0001943), Post-Traumatic Stress Disorder (EFO_0001358), Hyperglycemia (HP_0003074), Congestive Heart Failure (EFO_0000373), Ischemic Stroke (HP_0002140), Nicotine Dependence (EFO_0003768), Septic Shock (EFO_0006834), Hypertension (EFO_0000537), Parkinson Disease (MONDO_0005180), Acute Myocardial Infarction (EFO_0008583), Persian Gulf Syndrome (EFO_0007430), Acute Coronary Syndrome (EFO_0005672), Multiple System Atrophy (EFO_1001050), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Intermediate Coronary Syndrome (EFO_1000985), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Cardiac Arrest (EFO_0009492), Hypogonadism (MONDO_0002146), Insulin Resistance (EFO_0002614), Premature Birth (EFO_0003917), Sarcopenia (EFO_1000653), Stroke (EFO_0000712), Delirium (EFO_0009267), Chronic Progressive Multiple Sclerosis (EFO_0003840), Hypercholesterolemia (HP_0003124), Myocardial Infarction (EFO_0000612), Gestational Diabetes (EFO_0004593), Hyperinsulinemia (HP_0000842), Bipolar Disorder (MONDO_0004985), Schizophrenia (MONDO_0005090), Diabetic Neuropathy (EFO_1000783), Cognitive Impairment (HP_0100543), Burn (EFO_0009516), Acute Kidney Injury (HP_0001919), Major Depressive Disorder (MONDO_0002009), Hyperkalemia (HP_0002153), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6192', 'drugName': 'Insulin, Isophane', 'tradeNames_string': 'Ins hum insulat, Ins hum protaphane, Ins humulin i, Ins hypurin bov isop, Ins hypurin pore isop, Ins innolet insulat, Ins insulat, Ins insulat novolet, Ins insuman basal, Ins insuman basal optiset, Ins insuman basal solostar, Ins novolet hum protaphane, Ins pork insulat, Ins pur-in hum isop, Nph iletin, Penfill', 'drugSynonyms_string': 'Insulin injection, Insulin, isophane, Isophane (aqueous suspension), Isophane insulin', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148), Low Back Pain (HP_0003419), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3652', 'drugName': 'Insulin, Protamine Zinc', 'tradeNames_string': 'Ins hypurin bov prot zn, Ins prot zn bp', 'drugSynonyms_string': 'Insulin zinc protamine injection (aqueous suspension), Insulin, protamine zinc, Protamine zinc insulin, Protamine zinc insulin injection', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5441', 'drugName': 'Insulin Glulisine', 'tradeNames_string': 'Apidra, Apidra solostar, Ins apidra, Ins apidra opticlik, Ins apidra optiset, Ins apidra solostar', 'drugSynonyms_string': 'Glulisine apidra, HMR 1964, HMR-1964, HMR1964, Insulin Glulisine Recombinant, Insulin glulisine, Insulin glulisine recombinant, Insulin, glulisine, human, Insulin,glulisine,human', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Alzheimer Disease (MONDO_0004975), Down Syndrome (EFO_0001064), Myocardial Infarction (EFO_0000612), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2307', 'drugName': 'Insulin Zinc, Extended', 'tradeNames_string': 'Ins humulin zn, Ins ultrat, Ins ultrat mc, Ultralente, Ultralente iletin', 'drugSynonyms_string': 'Crystalline (aqueous suspension), Insulin zinc injection, Insulin zinc injection, crystalline (aqueous suspension), Insulin zinc suspension , Insulin zinc suspension (crystalline), Insulin zinc, extended', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1233', 'drugName': 'Insulin Zinc Susp Purified Pork', 'tradeNames_string': 'Lente, Lente iletin ii (pork)', 'drugSynonyms_string': 'Insulin zinc susp purified pork', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2302', 'drugName': 'Insulin Purified Beef', 'tradeNames_string': 'Regular iletin ii', 'drugSynonyms_string': 'Insulin (beef), Insulin purified beef', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5466', 'drugName': 'Insulin Pork', 'tradeNames_string': 'Iletin i, Insulin, Regular insulin', 'drugSynonyms_string': 'Insulin porcine, Insulin porcine insulin, Insulin pork', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Insulin Resistance (EFO_0002614), Coronary Artery Disease (EFO_0001645), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 1966, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5323', 'drugName': 'Insulin Peglispro', 'tradeNames_string': '', 'drugSynonyms_string': 'Insulin peglispro, LY-2605541, LY2605541', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4437', 'drugName': 'Insulin Human, Isophane', 'tradeNames_string': '', 'drugSynonyms_string': 'Insulin human, isophane', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_586', 'drugName': 'Insulin Tregopil', 'tradeNames_string': '', 'drugSynonyms_string': 'IN-105, Insulin tregopil', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1443 | Q17 | What gene does the drug Cns-5161 target? | The drug Cns-5161 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 7 genes: GRIN2B, GRIN2A, GRIN3A, GRIN2D, GRIN3B, GRIN1 and GRIN2C | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cns-5161%" OR LOWER(tradeNames_string) LIKE "%cns-5161%" OR LOWER(drugSynonyms_string) LIKE "%cns-5161%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2181', 'drugName': 'Cns-5161', 'tradeNames_string': '', 'drugSynonyms_string': 'Cns 5161, Cns-5161', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': -1, 'drugIsApproved': False, 'newLinkedTargets_string': 'GRIN1 (ENSG00000176884), GRIN2A (ENSG00000183454), GRIN2B (ENSG00000273079), GRIN2D (ENSG00000105464), GRIN3B (ENSG00000116032), GRIN2C (ENSG00000161509), GRIN3A (ENSG00000198785)', 'numberLinkedTargets': 7}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.836 | Q17 | What gene does the drug Ramipril target? | The drug Ramipril targets the gene ACE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ramipril%" OR LOWER(tradeNames_string) LIKE "%ramipril%" OR LOWER(drugSynonyms_string) LIKE "%ramipril%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6072', 'drugName': 'Ramipril', 'tradeNames_string': 'Altace, Lopace, Ramipril, Ranace, Tritace', 'drugSynonyms_string': 'C09AA05, Cardace, Corpril, Delix, Ecator, HOE 498, HOE-498, Hopace, NSC-758933, Pramace, Ramace, Ramipres, Ramipril, Triatec, Unipril, Vesdil', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Covid-19 (MONDO_0100096), Glomerulonephritis (MONDO_0002462), Systemic Lupus Erythematosus (MONDO_0007915), Metabolic Disease (EFO_0000589), Atrial Fibrillation (EFO_0000275), Myocardial Ischemia (EFO_1001375), Congestive Heart Failure (EFO_0000373), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Acute Myocardial Infarction (EFO_0008583), Atrial Flutter (EFO_0003911), Stroke (EFO_0000712), Abnormal Glucose Tolerance (EFO_0002546), Myocardial Infarction (EFO_0000612), Hypercholesterolemia (HP_0003124), Rheumatoid Arthritis (EFO_0000685), Albuminuria (EFO_0004285), Chronic Kidney Disease (EFO_0003884), Heart Disease (EFO_0003777), Diabetic Nephropathy (EFO_0000401), Heart Failure (EFO_0003144), Metabolic Syndrome (EFO_0000195), Kidney Disease (EFO_0003086), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.451 | Q17 | What gene does the drug Acemetacin target? | The drug Acemetacin targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acemetacin%" OR LOWER(tradeNames_string) LIKE "%acemetacin%" OR LOWER(drugSynonyms_string) LIKE "%acemetacin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3840', 'drugName': 'Acemetacin', 'tradeNames_string': 'Emflex', 'drugSynonyms_string': 'Acemetacin, NSC-757413, Rantudil', 'linkedDiseasesDrug_string': 'Rheumatic Disease (EFO_0005755)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.849 | Q17 | What gene does the drug Cosyntropin target? | The drug Cosyntropin targets the gene MC2R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cosyntropin%" OR LOWER(tradeNames_string) LIKE "%cosyntropin%" OR LOWER(drugSynonyms_string) LIKE "%cosyntropin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4137', 'drugName': 'Cosyntropin', 'tradeNames_string': 'Cortrosyn, Cosyntropin, Synacthen, Synacthen depot', 'drugSynonyms_string': 'Corticotropin tetracosapeptide, Cosyntropin, Cosyntropin acetate, Cosyntropin hexaacetate, Tetracosactide, Tetracosactide acetate, Tetracosactide hexaacetate, Tetracosactide hexacetate, Tetracosactrin, Vicotrope', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537), Membranous Glomerulonephritis (EFO_0004254), Developmental And Epileptic Encephalopathy (MONDO_0100062)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MC2R (ENSG00000185231)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1087 | Q17 | What gene does the drug Almotriptan target? | The drug Almotriptan targets 3 genes: HTR1B, HTR1F and HTR1D. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%almotriptan%" OR LOWER(tradeNames_string) LIKE "%almotriptan%" OR LOWER(drugSynonyms_string) LIKE "%almotriptan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3460', 'drugName': 'Almotriptan Malate', 'tradeNames_string': 'Almotriptan malate, Axert', 'drugSynonyms_string': 'Almogran, Almotriptan d,l-hydrogenmalate, Almotriptan malate, Almotriptan maleate, LAS 31416 D,L-MALATE ACID, LAS-31416, LAS-31416 D,L-MALATE ACID, LAS-31416-D,L-MALATE-ACID, PNU-180638E', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2781', 'drugName': 'Almotriptan', 'tradeNames_string': '', 'drugSynonyms_string': 'Almotriptan, LAS 31416, LAS-31416, NSC-760092', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2780', 'drugName': 'Almotriptan', 'tradeNames_string': '', 'drugSynonyms_string': 'Almotriptan, LAS 31416, LAS-31416, NSC-760092', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3458', 'drugName': 'Almotriptan Malate', 'tradeNames_string': 'Almotriptan malate, Axert', 'drugSynonyms_string': 'Almogran, Almotriptan d,l-hydrogenmalate, Almotriptan malate, Almotriptan maleate, LAS 31416 D,L-MALATE ACID, LAS-31416, LAS-31416 D,L-MALATE ACID, LAS-31416-D,L-MALATE-ACID, PNU-180638E', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3459', 'drugName': 'Almotriptan Malate', 'tradeNames_string': 'Almotriptan malate, Axert', 'drugSynonyms_string': 'Almogran, Almotriptan d,l-hydrogenmalate, Almotriptan malate, Almotriptan maleate, LAS 31416 D,L-MALATE ACID, LAS-31416, LAS-31416 D,L-MALATE ACID, LAS-31416-D,L-MALATE-ACID, PNU-180638E', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2782', 'drugName': 'Almotriptan', 'tradeNames_string': '', 'drugSynonyms_string': 'Almotriptan, LAS 31416, LAS-31416, NSC-760092', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1420 | Q17 | What gene does the drug Etodolac target? | The drug Etodolac targets the gene PTGS2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%etodolac%" OR LOWER(tradeNames_string) LIKE "%etodolac%" OR LOWER(drugSynonyms_string) LIKE "%etodolac%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_916', 'drugName': 'Etodolac', 'tradeNames_string': 'Ebretin, Etodolac, Etolyn, Etopan xl, Lodine, Lodine sr, Lodine xl, Ramodar', 'drugSynonyms_string': '(rs)-etodolic acid, AY-24,236, AY-24-236, AY-24236, Eccoxolac, Edolan, Etodolac, Etodolic acid, Flancox, Lodin xl, NIH-9918, NSC-282126, Napilac, Tedolan, Ultradol, Zedolac', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Rheumatic Disease (EFO_0005755), Osteoarthritis (MONDO_0005178), Muscular Disease (EFO_0002970), Juvenile Idiopathic Arthritis (EFO_0002609), Colorectal Neoplasm (EFO_0004142), Pain (EFO_0003843), Fish-Eye Disease (Orphanet_79292), Sprain (EFO_0009582), Rheumatoid Arthritis (EFO_0000685), Pancreatic Neoplasm (EFO_0003860)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4358', 'drugName': 'Sdx-101', 'tradeNames_string': '', 'drugSynonyms_string': '(-)-(r)-etodolac, (-)-etodolac, Etodolac, (-)-, Etodolac, (r)-, KS-1056, R-etodolac, RAK-593, SDX-101, Sdx-101', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Chronic Lymphocytic Leukemia (EFO_0000095)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'RXRA (ENSG00000186350)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1154 | Q17 | What gene does the drug Sorbinil target? | The drug Sorbinil is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene AKR1B1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sorbinil%" OR LOWER(tradeNames_string) LIKE "%sorbinil%" OR LOWER(drugSynonyms_string) LIKE "%sorbinil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2353', 'drugName': 'Sorbinil', 'tradeNames_string': '', 'drugSynonyms_string': 'CP-45,634, CP-45634, NSC-355082, Sorbinil', 'linkedDiseasesDrug_string': 'Diabetic Retinopathy (EFO_0003770)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'AKR1B1 (ENSG00000085662)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1826 | Q17 | What gene does the drug Nitroglycerin target? | The drug Nitroglycerin targets 4 genes: GUCY1A1, GUCY1B2, GUCY1A2 and GUCY1B1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nitroglycerin%" OR LOWER(tradeNames_string) LIKE "%nitroglycerin%" OR LOWER(drugSynonyms_string) LIKE "%nitroglycerin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1910', 'drugName': 'Nitroglycerin', 'tradeNames_string': 'Coro-nitro, Deponit 10, Deponit 5, Glytrin, Gonitro, Lenitral 7.5, Minitran, Minitran 10, Minitran 15, Minitran 5, Natirose, Nitriderm tts, Nitro iv, Nitro-bid, Nitro-dur, Nitro-mack ret, Nitrocine, Nitrocontin continus, Nitroglycerin, Nitrol, Nitrolingual, Nitrolingual pumpspray, Nitromin, Nitromist, Nitronal, Nitrostat, Percutol, Rectiv, Rectogesic, Suscard buccal, Sustac, Transderm-nitro, Transiderm-nitro 10, Transiderm-nitro 5, Tridil, Trintek 10, Trintek 15, Trintek 5', 'drugSynonyms_string': 'C01DA02, Chlormethine oxide hydrochloride, Diluted nitroglycerin, Glonoinum, Glyceryl Trinitrate, Glyceryl trinitrate, Glyceryl trinitrate solution, Imx-150, Mechlorethamine oxide hcl, Mitomen, Mustron, Nitora, Nitroglycerin, Nitroglycerin tablets, Nitromin hydrochloride, Transderm-Nitro, Trinitrin, Trinitrin tablets, Trinitrine', 'linkedDiseasesDrug_string': 'Erectile Dysfunction (EFO_0004234), Coronary Artery Disease (EFO_0001645), Pulmonary Hypertension (MONDO_0005149), Infection (EFO_0000544), Peripheral Arterial Disease (EFO_0004265), Pain (EFO_0003843), Injury (EFO_0000546), Hypotension (EFO_0005251), Muscle Cramp (EFO_0009846), Colorectal Carcinoma (EFO_1001951), Hot Flashes (HP_0031217), Scleroderma (EFO_1001993), Myocardial Ischemia (EFO_1001375), Osteoporosis (EFO_0003882), Osteopenia (HP_0000938), Congestive Heart Failure (EFO_0000373), Angina Pectoris (EFO_0003913), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Tendinitis (MONDO_0004857), Stroke (EFO_0000712), Hemorrhoid (EFO_0009552), Shock (HP_0031273), Myocardial Infarction (EFO_0000612), Inflammation (MP_0001845), Rheumatoid Arthritis (EFO_0000685), Rectum Cancer (EFO_1000657), Diabetic Neuropathy (EFO_1000783), Ischemia Reperfusion Injury (EFO_0002687), Lung Cancer (MONDO_0008903), Heart Failure (EFO_0003144), Non-Small Cell Lung Carcinoma (EFO_0003060), Raynaud Disease (EFO_1001145), Phlebitis (EFO_1001395)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GUCY1B1 (ENSG00000061918), GUCY1B2 (ENSG00000123201), GUCY1A2 (ENSG00000152402), GUCY1A1 (ENSG00000164116)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.588 | Q17 | What gene does the drug Ripasudil target? | The drug Ripasudil is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: ROCK2 and ROCK1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ripasudil%" OR LOWER(tradeNames_string) LIKE "%ripasudil%" OR LOWER(drugSynonyms_string) LIKE "%ripasudil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4729', 'drugName': 'Ripasudil', 'tradeNames_string': '', 'drugSynonyms_string': 'Ripasudil', 'linkedDiseasesDrug_string': "Fuchs Endothelial Corneal Dystrophy (Orphanet_98974), Fuchs' Endothelial Dystrophy (MONDO_0005321), Retinopathy Of Prematurity (EFO_1001158), Glaucoma (MONDO_0005041)", 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ROCK2 (ENSG00000134318), ROCK1 (ENSG00000067900)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3111', 'drugName': 'Ripasudil Hydrochloride Dihydrate', 'tradeNames_string': '', 'drugSynonyms_string': 'Glanatec, K-115, K-115-R, Ripasudil hydrochloride dihydrate, Ripasudil hydrochloride hydrate', 'linkedDiseasesDrug_string': "Fuchs' Endothelial Dystrophy (MONDO_0005321)", 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ROCK2 (ENSG00000134318), ROCK1 (ENSG00000067900)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1892 | Q17 | What gene does the drug Trospium Chloride target? | The drug Trospium Chloride targets 2 genes: CHRM2 and CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trospium chloride%" OR LOWER(tradeNames_string) LIKE "%trospium chloride%" OR LOWER(drugSynonyms_string) LIKE "%trospium chloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4683', 'drugName': 'Trospium Chloride', 'tradeNames_string': 'Flotros, Regurin, Regurin xl, Sanctura, Sanctura xr, Spasmo-lyt, Trospium chloride, Uraplex', 'drugSynonyms_string': 'IP-631, IP631, Relaspium, Spasmex, Spasmolyt, Trospium chloride', 'linkedDiseasesDrug_string': 'Urgency Urinary Incontinence (EFO_0006865), Schizophrenia (MONDO_0005090), Overactive Bladder (EFO_1000781), Chronic Obstructive Pulmonary Disease (EFO_0000341)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM2 (ENSG00000181072)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4684', 'drugName': 'Trospium Chloride', 'tradeNames_string': 'Flotros, Regurin, Regurin xl, Sanctura, Sanctura xr, Spasmo-lyt, Trospium chloride, Uraplex', 'drugSynonyms_string': 'IP-631, IP631, Relaspium, Spasmex, Spasmolyt, Trospium chloride', 'linkedDiseasesDrug_string': 'Urgency Urinary Incontinence (EFO_0006865), Schizophrenia (MONDO_0005090), Overactive Bladder (EFO_1000781), Chronic Obstructive Pulmonary Disease (EFO_0000341)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM2 (ENSG00000181072)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1970 | Q17 | What gene does the drug Hydrocortisone Hemisuccinate target? | The drug Hydrocortisone Hemisuccinate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hydrocortisone hemisuccinate%" OR LOWER(tradeNames_string) LIKE "%hydrocortisone hemisuccinate%" OR LOWER(drugSynonyms_string) LIKE "%hydrocortisone hemisuccinate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1752', 'drugName': 'Hydrocortisone Hemisuccinate', 'tradeNames_string': '', 'drugSynonyms_string': 'Hydrocortisone Hemisuccinate, Hydrocortisone succinate, NSC-757049, NSC-7576', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Leukemia (EFO_0000565), Septic Shock (EFO_0006834), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Acute Lymphoblastic Leukemia (EFO_0000220), Anaplastic Large Cell Lymphoma (EFO_0003032), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Burkitts Lymphoma (EFO_0000309), Diffuse Large B-Cell Lymphoma (EFO_0000403)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.668 | Q17 | What gene does the drug Bemarituzumab target? | The drug Bemarituzumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene FGFR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bemarituzumab%" OR LOWER(tradeNames_string) LIKE "%bemarituzumab%" OR LOWER(drugSynonyms_string) LIKE "%bemarituzumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1433', 'drugName': 'Bemarituzumab', 'tradeNames_string': '', 'drugSynonyms_string': 'Bemarituzumab, FPA-144', 'linkedDiseasesDrug_string': 'Adenocarcinoma (EFO_0000228), Non-Small Cell Lung Carcinoma (EFO_0003060), Gastric Cancer (MONDO_0001056), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.442 | Q17 | What gene does the drug Ivosidenib target? | The drug Ivosidenib targets the gene IDH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ivosidenib%" OR LOWER(tradeNames_string) LIKE "%ivosidenib%" OR LOWER(drugSynonyms_string) LIKE "%ivosidenib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1675', 'drugName': 'Ivosidenib', 'tradeNames_string': 'Tibsovo', 'drugSynonyms_string': 'AG-120, Ivosidenib', 'linkedDiseasesDrug_string': 'Chondrosarcoma (EFO_0000333), Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Acute Myeloid Leukemia (EFO_0000222), Glioma (EFO_0005543), Myelodysplastic Syndrome (EFO_0000198), Cholangiocarcinoma (EFO_0005221)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IDH1 (ENSG00000138413)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1857 | Q17 | What gene does the drug Sacubitril target? | The drug Sacubitril targets the gene MME. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sacubitril%" OR LOWER(tradeNames_string) LIKE "%sacubitril%" OR LOWER(drugSynonyms_string) LIKE "%sacubitril%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1487', 'drugName': 'Sacubitril', 'tradeNames_string': '', 'drugSynonyms_string': 'AHU-377, AHU377, Sacubitril', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Pulmonary Hypertension (MONDO_0005149), Aortic Valve Insufficiency (EFO_0007148), Peripheral Arterial Disease (EFO_0004265), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Covid-19 (MONDO_0100096), Essential Hypertension (MONDO_0001134), Myocardial Infarction (EFO_0000612), Acute Myocardial Infarction (EFO_0008583), St Elevation Myocardial Infarction (EFO_0008585), Hypertrophic Cardiomyopathy (EFO_0000538), Chagas Cardiomyopathy (EFO_0005529)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MME (ENSG00000196549)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.382 | Q17 | What gene does the drug Hydroxychloroquine target? | The drug Hydroxychloroquine targets 2 genes: TLR9 and TLR7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hydroxychloroquine%" OR LOWER(tradeNames_string) LIKE "%hydroxychloroquine%" OR LOWER(drugSynonyms_string) LIKE "%hydroxychloroquine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_963', 'drugName': 'Hydroxychloroquine', 'tradeNames_string': '', 'drugSynonyms_string': 'Hydroxychloroquine, Polirreumin', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Rheumatic Disease (EFO_0005755), Chronic Lymphocytic Leukemia (EFO_0000095), Infection (EFO_0000544), Pneumonia (EFO_0003106), Sjogren Syndrome (EFO_0000699), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Systemic Lupus Erythematosus (MONDO_0007915), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Ulcerative Colitis (EFO_0000729), Lung Disease (EFO_0003818), Coronavirus Infectious Disease (EFO_0007224), Malaria (EFO_0001068), Cutaneous Lupus Erythematosus (EFO_0003834), Prostate Carcinoma (EFO_0001663), Pregnancy (EFO_0002950), Temporal Arteritis (EFO_1001209), Hepatocellular Carcinoma (EFO_0000182), Hepatitis C Virus Infection (EFO_0003047), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Crohn'S Disease (EFO_0000384), Preeclampsia (EFO_0000668), Zellweger Syndrome (Orphanet_912), Lymphangioleiomyomatosis (MONDO_0011705), Colorectal Neoplasm (EFO_0004142), Osteoarthritis, Knee (EFO_0004616), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Mastocytosis (EFO_0009001), Acute Myeloid Leukemia (EFO_0000222), Acute Respiratory Distress Syndrome (EFO_1000637), Interstitial Lung Disease (EFO_0004244), Retinitis Pigmentosa (MONDO_0019200), Antiphospholipid Syndrome (EFO_0002689), Cholangiocarcinoma (EFO_0005221), Malignant Glioma (MONDO_0100342), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Thrombocytopenia (HP_0001873), Insulin Resistance (EFO_0002614), Small Cell Lung Carcinoma (EFO_0000702), Pulmonary Sarcoidosis (DOID_13406), Viral Pneumonia (EFO_0007541), Lichen Planus (EFO_1000726), Porphyria Cutanea Tarda (MONDO_0015104), Chronic Progressive Multiple Sclerosis (EFO_0003840), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Habitual Abortion (EFO_1000954), Chronic Hepatitis C Virus Infection (EFO_0004220), Influenza (EFO_0007328), Rheumatoid Arthritis (EFO_0000685), Cutaneous Melanoma (EFO_0000389), Ovarian Cancer (MONDO_0008170), Osteosarcoma (EFO_0000637), Osteoarthritis (MONDO_0005178), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Adenocarcinoma (EFO_0000228), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Type 1 Diabetes Mellitus (MONDO_0005147), Respiratory Failure (EFO_0009686), Melanoma (EFO_0000756), Sarcoma (EFO_0000691), Cystic Fibrosis (MONDO_0009061), Pneumocystosis (EFO_0007448), Glioblastoma Multiforme (EFO_0000519), Type 2 Diabetes Mellitus (MONDO_0005148), Hidradenitis Suppurativa (EFO_1000710), Severe Acute Respiratory Syndrome (EFO_0000694), X-Linked Alport Syndrome (MONDO_0010520)", 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TLR7 (ENSG00000196664), TLR9 (ENSG00000239732)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_962', 'drugName': 'Hydroxychloroquine', 'tradeNames_string': '', 'drugSynonyms_string': 'Hydroxychloroquine, Polirreumin', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Rheumatic Disease (EFO_0005755), Chronic Lymphocytic Leukemia (EFO_0000095), Infection (EFO_0000544), Pneumonia (EFO_0003106), Sjogren Syndrome (EFO_0000699), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Systemic Lupus Erythematosus (MONDO_0007915), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Ulcerative Colitis (EFO_0000729), Lung Disease (EFO_0003818), Coronavirus Infectious Disease (EFO_0007224), Malaria (EFO_0001068), Cutaneous Lupus Erythematosus (EFO_0003834), Prostate Carcinoma (EFO_0001663), Pregnancy (EFO_0002950), Temporal Arteritis (EFO_1001209), Hepatocellular Carcinoma (EFO_0000182), Hepatitis C Virus Infection (EFO_0003047), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Crohn'S Disease (EFO_0000384), Preeclampsia (EFO_0000668), Zellweger Syndrome (Orphanet_912), Lymphangioleiomyomatosis (MONDO_0011705), Colorectal Neoplasm (EFO_0004142), Osteoarthritis, Knee (EFO_0004616), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Mastocytosis (EFO_0009001), Acute Myeloid Leukemia (EFO_0000222), Acute Respiratory Distress Syndrome (EFO_1000637), Interstitial Lung Disease (EFO_0004244), Retinitis Pigmentosa (MONDO_0019200), Antiphospholipid Syndrome (EFO_0002689), Cholangiocarcinoma (EFO_0005221), Malignant Glioma (MONDO_0100342), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Thrombocytopenia (HP_0001873), Insulin Resistance (EFO_0002614), Small Cell Lung Carcinoma (EFO_0000702), Pulmonary Sarcoidosis (DOID_13406), Viral Pneumonia (EFO_0007541), Lichen Planus (EFO_1000726), Porphyria Cutanea Tarda (MONDO_0015104), Chronic Progressive Multiple Sclerosis (EFO_0003840), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Habitual Abortion (EFO_1000954), Chronic Hepatitis C Virus Infection (EFO_0004220), Influenza (EFO_0007328), Rheumatoid Arthritis (EFO_0000685), Cutaneous Melanoma (EFO_0000389), Ovarian Cancer (MONDO_0008170), Osteosarcoma (EFO_0000637), Osteoarthritis (MONDO_0005178), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Adenocarcinoma (EFO_0000228), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Type 1 Diabetes Mellitus (MONDO_0005147), Respiratory Failure (EFO_0009686), Melanoma (EFO_0000756), Sarcoma (EFO_0000691), Cystic Fibrosis (MONDO_0009061), Pneumocystosis (EFO_0007448), Glioblastoma Multiforme (EFO_0000519), Type 2 Diabetes Mellitus (MONDO_0005148), Hidradenitis Suppurativa (EFO_1000710), Severe Acute Respiratory Syndrome (EFO_0000694), X-Linked Alport Syndrome (MONDO_0010520)", 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TLR7 (ENSG00000196664), TLR9 (ENSG00000239732)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3879', 'drugName': 'Hydroxychloroquine Sulfate', 'tradeNames_string': 'Ercoquin, Hydroxychloroquine sulfate, Oxichlorochine, Plaquenil, Quensyl, Quinoric', 'drugSynonyms_string': 'Ercoquin, Hydroxychloroquine Sulfate, Hydroxychloroquine sulfate, Hydroxychloroquine sulphate, NSC-4375, Oxichlorochine sulfate, Oxiklorin, Quensyl, TCMDC-123987', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cholangiocarcinoma (EFO_0005221), Rheumatic Disease (EFO_0005755), Covid-19 (MONDO_0100096), Cutaneous Melanoma (EFO_0000389), Systemic Lupus Erythematosus (MONDO_0007915), Interstitial Lung Disease (EFO_0004244), Rheumatoid Arthritis (EFO_0000685), Lung Disease (EFO_0003818), Antiphospholipid Syndrome (EFO_0002689), Cutaneous Lupus Erythematosus (EFO_0003834), Coronavirus Infectious Disease (EFO_0007224), Malaria (EFO_0001068), X-Linked Alport Syndrome (MONDO_0010520)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TLR9 (ENSG00000239732), TLR7 (ENSG00000196664)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3878', 'drugName': 'Hydroxychloroquine Sulfate', 'tradeNames_string': 'Ercoquin, Hydroxychloroquine sulfate, Oxichlorochine, Plaquenil, Quensyl, Quinoric', 'drugSynonyms_string': 'Ercoquin, Hydroxychloroquine Sulfate, Hydroxychloroquine sulfate, Hydroxychloroquine sulphate, NSC-4375, Oxichlorochine sulfate, Oxiklorin, Quensyl, TCMDC-123987', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cholangiocarcinoma (EFO_0005221), Rheumatic Disease (EFO_0005755), Covid-19 (MONDO_0100096), Cutaneous Melanoma (EFO_0000389), Systemic Lupus Erythematosus (MONDO_0007915), Interstitial Lung Disease (EFO_0004244), Rheumatoid Arthritis (EFO_0000685), Lung Disease (EFO_0003818), Antiphospholipid Syndrome (EFO_0002689), Cutaneous Lupus Erythematosus (EFO_0003834), Coronavirus Infectious Disease (EFO_0007224), Malaria (EFO_0001068), X-Linked Alport Syndrome (MONDO_0010520)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TLR9 (ENSG00000239732), TLR7 (ENSG00000196664)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1478 | Q17 | What gene does the drug Tofogliflozin target? | The drug Tofogliflozin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene SLC5A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tofogliflozin%" OR LOWER(tradeNames_string) LIKE "%tofogliflozin%" OR LOWER(drugSynonyms_string) LIKE "%tofogliflozin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1052', 'drugName': 'Tofogliflozin', 'tradeNames_string': '', 'drugSynonyms_string': 'CSG 452, CSG-452, CSG452, R-7201, RO-4998452, RO4998452, Tofogliflozin, Tofogliflozin hydrate, Tofogliflozin monohydrate', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Non-Alcoholic Steatohepatitis (EFO_1001249)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC5A2 (ENSG00000140675)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3252', 'drugName': 'Tofogliflozin', 'tradeNames_string': '', 'drugSynonyms_string': 'Tofogliflozin', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Non-Alcoholic Steatohepatitis (EFO_1001249)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC5A2 (ENSG00000140675)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.974 | Q17 | What gene does the drug Febuxostat target? | The drug Febuxostat targets the gene XDH. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%febuxostat%" OR LOWER(tradeNames_string) LIKE "%febuxostat%" OR LOWER(drugSynonyms_string) LIKE "%febuxostat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1230', 'drugName': 'Febuxostat', 'tradeNames_string': 'Adenuric, Uloric', 'drugSynonyms_string': 'Febuxostat, NSC-758874, TMX-67', 'linkedDiseasesDrug_string': 'Gout (EFO_0004274), Hyperuricemia (EFO_0009104), Angina Pectoris (EFO_0003913), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Kidney Disease (EFO_0003086), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Tumor Lysis Syndrome (EFO_1001479), Nephrolithiasis (EFO_0004253)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'XDH (ENSG00000158125)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1210 | Q17 | What gene does the drug Insulin Tregopil target? | The drug Insulin Tregopil is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene INSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%insulin tregopil%" OR LOWER(tradeNames_string) LIKE "%insulin tregopil%" OR LOWER(drugSynonyms_string) LIKE "%insulin tregopil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_586', 'drugName': 'Insulin Tregopil', 'tradeNames_string': '', 'drugSynonyms_string': 'IN-105, Insulin tregopil', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.318 | Q17 | What gene does the drug Aticaprant target? | The drug Aticaprant is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene OPRK1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aticaprant%" OR LOWER(tradeNames_string) LIKE "%aticaprant%" OR LOWER(drugSynonyms_string) LIKE "%aticaprant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_115', 'drugName': 'Aticaprant', 'tradeNames_string': '', 'drugSynonyms_string': 'Aticaprant, CERC-501, Cerc-501, JNJ-67953964-AAA, JSPA-0658, JSPA0658, Jnj-67953964, LY-2456302, LY2456302, Ly2456302', 'linkedDiseasesDrug_string': 'Anxiety (EFO_0005230), Major Depressive Disorder (MONDO_0002009), Nicotine Dependence (EFO_0003768), Treatment Resistant Depression (EFO_0009854)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.698 | Q17 | What gene does the drug Axicabtagene Ciloleucel target? | The drug Axicabtagene Ciloleucel targets the gene CD19. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%axicabtagene ciloleucel%" OR LOWER(tradeNames_string) LIKE "%axicabtagene ciloleucel%" OR LOWER(drugSynonyms_string) LIKE "%axicabtagene ciloleucel%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3857', 'drugName': 'Axicabtagene Ciloleucel', 'tradeNames_string': '', 'drugSynonyms_string': 'Axicabtagene ciloleucel, KTE-C19, Yescarta', 'linkedDiseasesDrug_string': 'Follicular Lymphoma (MONDO_0018906), Mantle Cell Lymphoma (EFO_1001469), Neoplasm (EFO_0000616), Neoplasm Of Mature B-Cells (EFO_0000096), Lymphoma (EFO_0000574), Diffuse Large B-Cell Lymphoma (EFO_0000403), Lymphoid Neoplasm (EFO_0001642)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD19 (ENSG00000177455)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1505 | Q17 | What gene does the drug Rauwolfia Serpentina target? | The drug Rauwolfia Serpentina targets 6 genes: ADRA2A, ADRA2C, ADRA1A, ADRA1D, ADRA2B and ADRA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rauwolfia serpentina%" OR LOWER(tradeNames_string) LIKE "%rauwolfia serpentina%" OR LOWER(drugSynonyms_string) LIKE "%rauwolfia serpentina%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4856', 'drugName': 'Rauwolfia Serpentina', 'tradeNames_string': 'Hiwolfia, Hyserpin, Koglucoid, Raudixin, Rauserpin, Rauval, Rauwolfia serpentina, Wolfina', 'drugSynonyms_string': 'Rauvolfia serpentina root, Rauwolfia alkaloids, Rauwolfia alkaloids, whole root, Rauwolfia serpentina, Rauwolfia serpentina alseroxylon, Rauwolfia serpentina root', 'linkedDiseasesDrug_string': 'Heart Disease (EFO_0003777), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1954, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.430 | Q17 | What gene does the drug Hydroxyprogesterone Caproate target? | The drug Hydroxyprogesterone Caproate targets the gene PGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hydroxyprogesterone caproate%" OR LOWER(tradeNames_string) LIKE "%hydroxyprogesterone caproate%" OR LOWER(drugSynonyms_string) LIKE "%hydroxyprogesterone caproate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4832', 'drugName': 'Hydroxyprogesterone Caproate', 'tradeNames_string': 'Delalutin, Hydroxyprogesterone caproate, Makena, Makena (autoinjector), Makena preservative free, Proluton depot', 'drugSynonyms_string': '17-ohpc, 17.alpha.-caproyloxy-p4, Depo-proluton, Hormofort, Hydroxyprogesterone, Hydroxyprogesterone caproate, Hydroxyprogesterone hexanoate, Hylutin, NSC-17592, Oxiprogesterone caproate, Pharlon, Primolut depot, Procyte depo, Proge, Syngynon, Teralutil', 'linkedDiseasesDrug_string': 'Pregnancy (EFO_0002950), Premature Birth (EFO_0003917)', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.601 | Q17 | What gene does the drug Fosinopril target? | The drug Fosinopril targets the gene ACE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fosinopril%" OR LOWER(tradeNames_string) LIKE "%fosinopril%" OR LOWER(drugSynonyms_string) LIKE "%fosinopril%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2110', 'drugName': 'Fosinopril', 'tradeNames_string': 'Monopril', 'drugSynonyms_string': 'C09AA09, Fosenopril, Fosinopril, SQ-28555', 'linkedDiseasesDrug_string': 'Heart Disease (EFO_0003777), Diabetic Nephropathy (EFO_0000401), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2506', 'drugName': 'Fosinopril Sodium', 'tradeNames_string': 'Fosinopril sodium, Fositens, Fozitec, Monopril, Staril', 'drugSynonyms_string': 'Fosenopril sodium, Fosinopril sodium, Fosinopril sodium salt, SQ 28555, SQ-28555', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1964 | Q17 | What gene does the drug Procyclidine target? | The drug Procyclidine targets the gene CHRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%procyclidine%" OR LOWER(tradeNames_string) LIKE "%procyclidine%" OR LOWER(drugSynonyms_string) LIKE "%procyclidine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5673', 'drugName': 'Procyclidine', 'tradeNames_string': '', 'drugSynonyms_string': 'Elorine, Kemadrine, Lergine, NSC-169103, Procyclidine, Tricoloid, Vagosin', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4919', 'drugName': 'Procyclidine Hydrochloride', 'tradeNames_string': 'Arpicolin, Kemadrin, Muscinil', 'drugSynonyms_string': 'NSC-757293, Procyclidine HCl, Procyclidine hcl, Procyclidine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.629 | Q17 | What gene does the drug Alfentanil Hydrochloride target? | The drug Alfentanil Hydrochloride targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alfentanil hydrochloride%" OR LOWER(tradeNames_string) LIKE "%alfentanil hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%alfentanil hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_793', 'drugName': 'Alfentanil Hydrochloride', 'tradeNames_string': 'Alfenta, Alfentanil, Rapifen, Rapifen conc, Rapifen dilute, Rapifen intensive care', 'drugSynonyms_string': 'Alfentanil hydrochloride, Alfentanil hydrochloride cii, Alfentanil hydrochloride monohydrate, R 39,209, R 39209, R-39,209, R-39209', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1170 | Q17 | What gene does the drug Amlodipine target? | The drug Amlodipine targets 4 genes: CACNA1C, CACNA1D, CACNA1S and CACNA1F. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amlodipine%" OR LOWER(tradeNames_string) LIKE "%amlodipine%" OR LOWER(drugSynonyms_string) LIKE "%amlodipine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6132', 'drugName': 'Levamlodipine Maleate', 'tradeNames_string': 'Conjupri', 'drugSynonyms_string': 'Amlodipine maleate, s-, Levamlodipine maleate', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_1168', 'drugName': 'Amlodipine', 'tradeNames_string': 'Astudal 5, Istin, Norvas, Norvasc', 'drugSynonyms_string': 'Amlodipine, CKD-330 COMPONENT AMLODIPINE, HGP-0904, HGP0904', 'linkedDiseasesDrug_string': "Diabetes Mellitus (EFO_0000400), Erectile Dysfunction (EFO_0004234), Hyperlipidemia (MONDO_0021187), Coronary Artery Disease (EFO_0001645), Liver Disease (EFO_0001421), Essential Hypertension (MONDO_0001134), Focal Dystonia (MONDO_0000477), Abdominal Aortic Aneurysm (EFO_0004214), Myocardial Ischemia (EFO_1001375), Congestive Heart Failure (EFO_0000373), Breast Cancer (MONDO_0007254), Angina Pectoris (EFO_0003913), Thalassemia (EFO_1001996), Aortic Valve Insufficiency (EFO_0007148), Prinzmetal'S Angina (EFO_1000013), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Fish-Eye Disease (Orphanet_79292), Stroke (EFO_0000712), Familial Hypercholesterolemia (EFO_0004911), Hypercholesterolemia (HP_0003124), Myocardial Infarction (EFO_0000612), Proteinuria (HP_0000093), Depressive Disorder (MONDO_0002050), Pancreatitis (EFO_0000278), Heart Disease (EFO_0003777), Hiv Infection (EFO_0000764), Heart Failure (EFO_0003144), Raynaud Disease (EFO_1001145), Kidney Disease (EFO_0003086), Beta-Thalassemia Major (MONDO_0016486), Primary Aldosteronism (MONDO_0001422), Hypertrophic Cardiomyopathy (EFO_0000538), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)", 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2584', 'drugName': 'Amlodipine Besylate', 'tradeNames_string': 'Amlodipine besylate, Norliqva, Norvasc', 'drugSynonyms_string': 'Amlodipine (as besilate), Amlodipine benzenesulfonate, Amlodipine besilate, Amlodipine besylate, Amlor, Antacal, Lodipressin, Monopina, NSC-758922, Norliqva, UK-48,340-26, UK-48340-26', 'linkedDiseasesDrug_string': "Hyperlipidemia (MONDO_0021187), Congestive Heart Failure (EFO_0000373), Coronary Artery Disease (EFO_0001645), Angina Pectoris (EFO_0003913), Familial Hypercholesterolemia (EFO_0004911), Prinzmetal'S Angina (EFO_1000013), Hypertension (EFO_0000537), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Fish-Eye Disease (Orphanet_79292), Hypercholesterolemia (HP_0003124), Proteinuria (HP_0000093), Essential Hypertension (MONDO_0001134)", 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_4057', 'drugName': 'Levamlodipine', 'tradeNames_string': '', 'drugSynonyms_string': 'Amlodipine, (s)-, Levamlodipine, S-amlodipine', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_352', 'drugName': 'Amlodipine Maleate', 'tradeNames_string': 'Amvaz', 'drugSynonyms_string': 'Amlodipine maleate, UK-48,340-11, UK-48340-11', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_5167', 'drugName': 'Amlodipine Benzoate', 'tradeNames_string': 'Katerzia', 'drugSynonyms_string': 'Amlodipine benzoate', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Stroke (EFO_0000712), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1254 | Q17 | What gene does the drug Vorasidenib target? | The drug Vorasidenib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: IDH1 and IDH2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vorasidenib%" OR LOWER(tradeNames_string) LIKE "%vorasidenib%" OR LOWER(drugSynonyms_string) LIKE "%vorasidenib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1864', 'drugName': 'Vorasidenib', 'tradeNames_string': '', 'drugSynonyms_string': 'AG-881, Ag-881, Vorasidenib', 'linkedDiseasesDrug_string': 'Astrocytoma (EFO_0000272), Central Nervous System Cancer (EFO_0000326)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'IDH1 (ENSG00000138413), IDH2 (ENSG00000182054)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.230 | Q17 | What gene does the drug Pilocarpine Hydrochloride target? | The drug Pilocarpine Hydrochloride targets 2 genes: CHRM3 and CHRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pilocarpine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%pilocarpine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%pilocarpine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5678', 'drugName': 'Pilocarpine Hydrochloride', 'tradeNames_string': 'Isopto carpine, Ocusert, Piloc hcl, Pilocarpine hydrochloride, Pilogel, Pilopine, Pilopine hs, Salagen, Sno pilo, Vuity', 'drugSynonyms_string': 'Pilocarpine hcl, Pilocarpine hydrochloride, Pilocarpine monohydrochloride, Pilocarpini hydrochloridum, Pilocarpinum muriaticum, Salagen, Vistacarpin n, Vuity', 'linkedDiseasesDrug_string': 'Presbyopia (MONDO_0001330), Head And Neck Malignant Neoplasia (EFO_0006859)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5679', 'drugName': 'Pilocarpine Hydrochloride', 'tradeNames_string': 'Isopto carpine, Ocusert, Piloc hcl, Pilocarpine hydrochloride, Pilogel, Pilopine, Pilopine hs, Salagen, Sno pilo, Vuity', 'drugSynonyms_string': 'Pilocarpine hcl, Pilocarpine hydrochloride, Pilocarpine monohydrochloride, Pilocarpini hydrochloridum, Pilocarpinum muriaticum, Salagen, Vistacarpin n, Vuity', 'linkedDiseasesDrug_string': 'Presbyopia (MONDO_0001330), Head And Neck Malignant Neoplasia (EFO_0006859)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1180 | Q17 | What gene does the drug Eprosartan Mesylate target? | The drug Eprosartan Mesylate targets the gene AGTR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eprosartan mesylate%" OR LOWER(tradeNames_string) LIKE "%eprosartan mesylate%" OR LOWER(drugSynonyms_string) LIKE "%eprosartan mesylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5528', 'drugName': 'Eprosartan Mesylate', 'tradeNames_string': 'Eprosartan mesylate, Teveten', 'drugSynonyms_string': 'Eprosartan mesilate, Eprosartan mesylate, Eprosartan monomethanesulfonate, SK&F 108566-J, SK&F-108566-J', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537), Essential Hypertension (MONDO_0001134)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AGTR1 (ENSG00000144891)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1332 | Q17 | What gene does the drug Methantheline Bromide target? | The drug Methantheline Bromide targets the gene HRH2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methantheline bromide%" OR LOWER(tradeNames_string) LIKE "%methantheline bromide%" OR LOWER(drugSynonyms_string) LIKE "%methantheline bromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3603', 'drugName': 'Methantheline Bromide', 'tradeNames_string': 'Banthine', 'drugSynonyms_string': 'Dixamone bromide, Methantheline bromide, Methanthelinium bromide, NSC-32145, Vagantin', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1951, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH2 (ENSG00000113749)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1587 | Q17 | What gene does the drug Flecainide target? | The drug Flecainide targets the gene SCN5A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%flecainide%" OR LOWER(tradeNames_string) LIKE "%flecainide%" OR LOWER(drugSynonyms_string) LIKE "%flecainide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5669', 'drugName': 'Flecainide', 'tradeNames_string': '', 'drugSynonyms_string': 'Flecainide, NSC-719273, THN-102 COMPONENT FLECAINIDE', 'linkedDiseasesDrug_string': 'Arrhythmogenic Right Ventricular Dysplasia (Orphanet_247), Pain (EFO_0003843), Cardiac Arrhythmia (EFO_0004269), Ventricular Arrhythmia (HP_0004308), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN5A (ENSG00000183873)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_605', 'drugName': 'Flecainide Acetate', 'tradeNames_string': 'Flecainide acetate, Tambocor', 'drugSynonyms_string': 'Flecainide acetate, Flecainide monoacetate', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Pain (EFO_0003843), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN5A (ENSG00000183873)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.69 | Q17 | What gene does the drug Nizatidine target? | The drug Nizatidine targets the gene HRH2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nizatidine%" OR LOWER(tradeNames_string) LIKE "%nizatidine%" OR LOWER(drugSynonyms_string) LIKE "%nizatidine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2673', 'drugName': 'Nizatidine', 'tradeNames_string': 'Axid, Axid ar, Nizatidine, Zinga 150, Zinga 300', 'drugSynonyms_string': 'Acinon, LY 139037, LY-139037, NSC-759289, Nizatidine', 'linkedDiseasesDrug_string': 'Esophagitis (HP_0100633), Duodenal Ulcer (EFO_0004607), Peptic Ulcer (HP_0004398), Gastritis (EFO_0000217), Gastroesophageal Reflux Disease (EFO_0003948), Gastroparesis (EFO_1000948)', 'yearOfFirstApproval': 1988, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH2 (ENSG00000113749)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.25 | Q17 | What gene does the drug Solanezumab target? | The drug Solanezumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene APP. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%solanezumab%" OR LOWER(tradeNames_string) LIKE "%solanezumab%" OR LOWER(drugSynonyms_string) LIKE "%solanezumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3274', 'drugName': 'Solanezumab', 'tradeNames_string': '', 'drugSynonyms_string': 'LY-2062430, LY2062430, Solanezumab', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Cognitive Impairment (HP_0100543)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'APP (ENSG00000142192)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.147 | Q17 | What gene does the drug Amineptine target? | The drug Amineptine targets 2 genes: DRD1 and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amineptine%" OR LOWER(tradeNames_string) LIKE "%amineptine%" OR LOWER(drugSynonyms_string) LIKE "%amineptine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2419', 'drugName': 'Amineptine', 'tradeNames_string': '', 'drugSynonyms_string': 'Amineptin, Amineptine', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD1 (ENSG00000184845)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.542 | Q17 | What gene does the drug Nusinersen Sodium target? | The drug Nusinersen Sodium targets the gene SMN2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nusinersen sodium%" OR LOWER(tradeNames_string) LIKE "%nusinersen sodium%" OR LOWER(drugSynonyms_string) LIKE "%nusinersen sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6328', 'drugName': 'Nusinersen Sodium', 'tradeNames_string': 'Spinraza', 'drugSynonyms_string': 'Nusinersen sodium', 'linkedDiseasesDrug_string': 'Spinal Muscular Atrophy (EFO_0008525)', 'yearOfFirstApproval': 2016, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SMN2 (ENSG00000205571)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.818 | Q17 | What gene does the drug Glpg-0259 target? | The drug Glpg-0259 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MAPKAPK5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%glpg-0259%" OR LOWER(tradeNames_string) LIKE "%glpg-0259%" OR LOWER(drugSynonyms_string) LIKE "%glpg-0259%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_513', 'drugName': 'Glpg-0259', 'tradeNames_string': '', 'drugSynonyms_string': 'GLPG-0259, GLPG0259, Glpg-0259', 'linkedDiseasesDrug_string': 'Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAPKAPK5 (ENSG00000089022)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1120 | Q17 | What gene does the drug Epoetin Zeta target? | The drug Epoetin Zeta targets the gene EPOR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%epoetin zeta%" OR LOWER(tradeNames_string) LIKE "%epoetin zeta%" OR LOWER(drugSynonyms_string) LIKE "%epoetin zeta%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4677', 'drugName': 'Epoetin Zeta', 'tradeNames_string': 'Retacrit', 'drugSynonyms_string': 'Epoetin, Epoetin zeta, Erythropoietin, Erythropoietin for bioassays', 'linkedDiseasesDrug_string': 'Diabetic Foot (EFO_1001459)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EPOR (ENSG00000187266)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.88 | Q17 | What gene does the drug Cisapride target? | The drug Cisapride targets the gene HTR4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cisapride%" OR LOWER(tradeNames_string) LIKE "%cisapride%" OR LOWER(drugSynonyms_string) LIKE "%cisapride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3176', 'drugName': 'Cisapride', 'tradeNames_string': 'Alimix, Prepulsid, Prepulsid quicklet, Propulsid, Propulsid quicksolv', 'drugSynonyms_string': 'Cisapride, Cisapride monohydrate, Propulsid, R-51,619, R-51619', 'linkedDiseasesDrug_string': 'Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.